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A STUDY ON DIASTOLIC DYSFUNCTION IN 
ASYMPTOMATIC TYPE 2 DIABETES MELLITUS 
WITH NORMAL SYSTOLIC FUNCTION 
 
INTRODUCTION 
 
The incidence of diabetes mellitus (DM) is on the raise across the world 
and it is turning out to be an epidemic of non communicable disease. Diabetic 
heart disease and Diabetic Cardiomyopathy as a separate entity has been 
proposed in the last couple of decades. Diastolic heart failure, otherwise called 
as heart failure with preserved ejection fraction, is common finding of 
hypertensive heart disease, but various studies report a high incidence of 
diastolic heart failure in patients with type 2 diabetes mellitus inspite of the 
absence of coronary artery heart disease and hypertension.  Observations point 
to a diastolic dysfunction occurring before systolic dysfunction in the setting of 
myocardial damage due to diabetes. There is also prevalence of a pre-clinical 
diastolic dysfunction in diabetics. The patho-physiology of an impaired diastolic 
dysfunction in diabetes is poorly understood. Diabetic cardiomyopathy is 
proposed to be a disease independent coronary artery disease. Metabolic 
derangements involving hyperglycemia, hyperlipidemia, hyperinsulinemia, 
myocyte loss, interstitial fibrosis, autonomic neuropathy, microvascular 
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dysfunction have all been proposed as underlying the development of Diabetic 
cardiomyopathy. The objective of this study is to find out the association 
between Type 2 Diabetes Mellitus and Diastolic Dysfunction, even in the 
asymptomatic diabetic population. To ascertain the prevalence of left ventricular 
diastolic dysfunction and to determine its correlation with duration of diabetes 
mellitus, obesity parameters, HbA1c levels, patient’s age and diabetic 
microvascular complications we conducted this case control study. 
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AIM 
1) To determine the prevalence of dysfunction of left ventricle in diastole in 
type 2 diabetes mellitus patients with duration greater than 5 years  
2) To compare the prevalence of left ventricular diastolic dysfunction of non 
diabetic individuals with that of asymptomatic type II diabetes patients 
3) To know the correlation of diastolic dysfunction in diabetes with age of 
patients, HbA1c levels, duration of diabetes, duration of diabetes, 
retinopathy, autonomic neuropathy. 
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 Diabetes affects the heart in 3 ways:  
(1) Coronary Artery Disease (CAD) due to accelerated atherosclerosis 
(2) Cardiac Autonomic Neuropathy (CAN) and  
(3) Diabetic Cardiomyopathy (DbCM).  
 Although there is high awareness among clinicians about the first two 
disease entities, DbCM is poorly recognized by most physicians and 
diabetologists.  
Various studies have reported the presence of cardiac abnormality apart from 
coronary artery disease in asymptomatic diabetes patients. 
 In 1991 Galderisi et al reported the incidence of increased left 
ventricular mass in diabetes mellitus in women through the Framingham heart 
study. In 1997 Lee et al reported the presence of increased left ventricular mass 
in diabetes mellitus in both men and women in the cardiovascular health study. 
In 2000, Devereux et al in Strong health study showed that there is increased 
left ventricular mass, decreased endocardial fractional shortening and midwall 
fractional shortening in diabetes mellitus. In 2001 Ilercil et al showed that there 
is increased left ventricular thickness and relative wall thickness in impaired 
glucose tolerance. In 2003Rutter et al used Framingham heart study and reported 
the presence of progressive increase in left ventricular mass, relative wall 
thickness in both impaired glucoe tolerance and diabetes mellitus. 
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 Poulsen et al in a study of 300 patients in 2010 observed that there is high 
prevalence of diastolic dysfunction in patients with type 2 diabetes with no 
previous history of coronary artery disease and abnormal left ventricular filling 
was associated with impaired myocardial perfusion. 
 Soldatos et al did a case control study with 60 patients and found a 
significant incidence of diastolic dysfunction in diabetic individuals. 
 Masugata et al conducted a case control study with 78 patients with 
normal blood pressure. He found the the presence of diastolic dysfunction with 
normal systolic function was correlating to duration of type 2 diabetes and age 
of patients. 
 Mishra et al observed, from their case control study of 70 patients, that 
when compared to normal individuals, patients with diabetes have reduced 
diastolic and systolic function. He also found that the systolic and diastolic 
disturbances were correlating with diabetes duration and the microvascular 
complications. 
 Between 1996-2007  From et al conducted a study with 485 subjects and 
observed that diastolic dysfunction of left ventricle was associated with diabetes 
mellitus with duration > 4 years. 
 Sohail et al in a study with 211 patients observed a 30% incidence of 
diastolic dysfunction in type 2 diabetes. 
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 Exiara et al in a study with 115 patients observed that, patients without 
hypertension and properly controlled diabetes have diastolic dysfunction and it 
correlates with duration of diabetes. 
 Diamant et al found that the echo findings of E, A, E/A ratio and other 
diastolic function indices were decreased in uncomplicated diabetes that was 
diagnosed recently. 
 Bonito et al states that the left ventricular diastolic dysfunction correlates 
with micro vascular complications. 
 Aaron et al with a study of 1700 patients found a 23 % incidence of 
diastolic dysfunction in type 2 diabetes. 
 Takeda et al in a study of 500 Japanese diabetes patients observed that 
there is a major role for diastolic dysfunction in producing heart failure with 
preserved systolic function. 
 Poanta et al observed, through a study of 50 patients, that left ventricular 
diastolic dysfunction was associated with cardiac autonomic neuropathy which 
was asymptomatic. 
 Patil et al in a study with 122 diabetes patients found that the prevalence 
of left ventricular diastolic dysfunction was high in diabetics who are 
asymptomatic, which correlated with HBA1c levels, obesity parameters, 
duration of diabetes and the microvascular complications. 
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DIABETES MELLITUS 
 A group of common metabolic disorders producing a phenotypic 
expression of hyperglycemia is termed as Diabetes Mellitus. The dysregulation 
in metabolism due to diabetes affects multiple organ system and leads to a 
number of complications. Diabetes is one of the major causes of end stage renal 
disease (ESRD), adult blindness, non traumatic lower limb amputation, coronary 
artery disease, etc 
 Diabetes mellitus may be caused by defective production of insulin or by 
the resistance to respond appropriately to insulin, leading to hyperglycemia.. 
Type 1 Diabetes mellitus is due to total lack of insulin production caused by 
auto immune destruction of beta cells of pancreas. In type 2 diabetes, there is a 
insulin resistance in the peripheral tissues, like skeletal muscles, adipose tissue 
and liver on which insulin acts, which is the basic patho physiology, leading to 
initially a relative insulin deficiency that later on progresses to predominant 
insulin secretory defect with insulin resistance.  
 Other specific types of diabetes do exist. These include genetic defects in 
beta cell function due to mutations, defects in insulin action due to genetic 
mutations, disorders affecting the exocrine pancreas, specific endocrinopathies, 
drug induced diabetes, gestational diabetes mellitus 
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The diagnosis of diabetes is made based on the following criteria  
TABLE 1: DIAGNOSTIC CRITERIA TO DEFINE DIABETES MELLITUS 
SL 
NO 
PARAMETER NORMAL GLYCEMIC 
STATUS 
PRE-DIABETES DIABETES 
1. FASTING PLASMA 
GLUCOSE 
<5.6 mmol/l or 
100mg/dl 
5.6-6.9 mmol/l 
or 
100-125 mg/dl 
>/= 7mmol/l or 
>126mg/dl 
2. 2 HOUR PLASMA 
GLUCOSE AFTER 
GLUCOSE CHALLENGE 
<7.8 mmol/l or 
140 mg/dl 
7.8-11mmol/l or 
140-199 mg/dl 
>/=11.1mmol/l 
or 
>200mg/dl 
3. HB A 1 C <5.6% 5.7-6.4 % >/=6.5% 
 The above criteria was issued by an International expert committee with 
members appointed by the American Diabetes Association(ADA), the European 
Association for the Study of Diabetes and the International Diabetes Federation. 
 The pre diabetes stage may be either an impaired fasting glucose (IFG) 
with fasting plasma glucose of 100-125 mg/dl, or, an impaired glucose tolerance 
following a 75 g of oral glucose tolerance test with plasma glucose levels of 
140-199 mg/dl 2 hour following the glucose ingestion. 
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 Diabetes was estimated to affect over 180 million people in 2008 all over 
the world. Complicating the high burden of disease is the increased incidence 
and prevalence of type 2diabetes, propelled by increasing age of population, 
obesity, and sedentary life style as well as by the increased longevity of patients 
with type 2 DM. It is predicted that by 2030 the presence of diabetes might 
double the number as it is in the present day. 
DIABETIC CARDIOMYOPATHY 
 Historically most of the attention has been focused on the prevention and 
treatment of micro-vascular diseases complicating diabetes such as diabetic 
retinopathy, diabetic nephropathy, and diabetic neuropathy. But cardiovascular 
disease is the major cause for disability and death in diabetes mellitus. The most 
common cardiovascular abnormality is coronary artery heart disease (CAHD). 
Diabetes also increases the risk of cerebrovascular disease like stroke, peripheral 
vascular disease due to accelerated atherosclerosis, and also heart failure both 
systolic and diastolic.  
 In 1972 Rubler et al first described Diabetic Cardiomyopathy . “Diabetic 
cardiomyopathy is defined as myocardial dysfunction occurring in patients 
with diabetes in the absence of Coronary Artery heart Disease, hypertension, 
or valvular heart disease.”  
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ATHEROSCLEROSIS  
 When compared with non-diabetic population, patients with diabetes 
mellitus have a 2-fold to 4-fold increased risk of developing Coronary heart 
disease and also of dying from it. The occurrence of diabetes mellitus is 
considered to be a “Coronary Disease Equivalent” meaning that the risk of 
coronary events in a diabetic patient is equal to that of a non diabetic individual 
who sustained an Acute myocardial infarction. Of late with more effective 
therapy and awareness, the coronary artery heart disease risk has been 
substantially lowered in the last decade.  
 Diabetes mellitus is associated with an increased risk for Myocardial 
infarction both the ST elevation Myocardial Infarction and Non-ST elevation 
Myocardial Infarction, Unstable angina and Chronic stable angina. The 
incidence of these events is more than 1 in 3 patients. The outcome following 
these Acute Coronary Syndromes (ACS) is poor in patients with diabetes when 
compared to that of non diabetes. Inspite of overall improvement in outcome 
over the past several decades for both patients with diabetes and without 
diabetes, the graveness of risk associated with diabetes still persists . 
 In addition to CHD, diabetes increases the risks of stroke and peripheral 
arterial disease. The diagnosis of diabetes portends a twofold increased stroke 
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risk compared with non diabetic individuals , with hyperglycemia affecting 
approximately one in three patients with acute stroke, associated with a twofold 
to sixfold increased risk for adverse clinical outcomes after stroke. Among 
patients with symptomatic peripheral arterial disease, diabetes prevalence ranges 
from 20% to 30% and accounts for approximately 50% of all lower extremity 
amputations . 
HEART FAILURE:  
 In the ambulatory setting, diabetes associates independently with a 
twofold to fivefold increase in risk for heart failure (HF), comprising both 
systolic and diastolic HF, and diabetes patients have worse outcomes once HF 
has developed. In addition, diabetes is associated with an increased HF risk in 
the setting of Acute Coronary Syndrome event. The increased risk of HF 
observed in diabetes is multi factorial, caused by ischemic, metabolic, and 
functional myocardial perturbations. 
  Diabetes as risk factor in the development of heart failure is well known 
and the Framingham Heart Study confirmed that the occurrence of heart failure 
in diabetic individuals compared to age-matched control subjects very high. 
Heart failure reduces the quality of life of the affected individual and 
complicates the management of diabetes by alterations in the pharmacokinetics 
22 
 
of anti-diabetic medications. Therefore, early diagnosis and prompt management 
of these patients are of utmost importance. 
EPIDEMIOLOGY 
 Heart failure prevalence among diabetic individuals was as high as 20-
25% in major clinical trials. However the actual prevalence of Diabetic 
Cardiomyopathy  is not yet established, since there is a lack of large scale study 
data from different populations with diabetes mellitus. Some studies reported the 
prevalence upto 30% - 60 %.The small size of sample population limit the utility 
of these studies. The  prevalence of myocardial dysfunction and heart failure 
was found to be 14.5% and 3.7% respectively at 7 years of follow up in a major 
prospective study which examined the prevalence of heart failure and 
myocardial dysfucntion in patients with type 1 diabetes of more than 10 years 
duration. The annual incidenc of heart failure was 0.01% and myocardial 
dysfunction was 0.02%. However 85% of patients were found to have a diastolic 
heart failure in the baseline evaluation. 
 The question whether diabetes itself, distinct from CAD and 
hypertension, results in a dilated cardiomyopathy, remains 
controversial. Analysing the Framingham heart study,  it was found, 
in the population group of age between 35-64 yrs there is a 4 fold 
increased risk of heart failure in men and risk as high as 8 fold in 
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women even after the results were adjusted for other variables lik e 
lipid profile, age of the population studied, blood pressure ,obesity 
indices and prior history of CAD. The Washington DC Dilated 
Cardiomyopathy Study which was concluded recently also in the 
final analysis showed the association of diabetes with idiopat hic 
cardiomyopathy.  
 Persons with diabetes, and especially women, have greater left 
ventricular mass and higher heart rates than their nondiabetic 
counterparts. Some studies report that patients with diabetes may 
have an abnormal exercise response, with an  attenuation or 
augmentation of left ventricular EF relative to that of healthy 
persons without diabetes. Furthermore, various groups have reported 
diastolic abnormalities using various parameters, including 
prolonged isovolumic relaxation time decreased rates of left 
ventricular diastolic filling and abnormal transmitral flow v elocities. 
Increased echo density has also been reported despite normal wall 
thicknesses, which could suggest increased collagen deposition 
present in the myocardium .  
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PATHOGENESIS AND PATHOPHYSIOLOGY 
 Pathologically, postmortem studies of patients with diabetic 
cardiomyopathy have revealed that they have features similar to 
those of patients with other forms of nonischemic cardiomyopathy. 
This includes myocyte hypertrophy, intersti tial fibrosis, and 
infiltration with periodic acid-Schiff–positive materials, with 
coronary arterioles having thickened basement membranes, as well 
as the presence of intramyocardial microangiopathy.  
 Theories abound regarding the possible mechanism or 
mechanisms underlying diabetic cardiomyopathy. These include both 
cellular and molecular perturbations, as well as metabolic 
abnormalities. 
  Insulin may play a central role in the cellular and molecular 
mechanisms of diabetic cardiomyopathy. Studies with a l ine of 
transgenic mice in which the gene for the insulin -regulated glucose 
transporter GLUT4 has been deleted demonstrate hyperinsulinemia 
and cardiomyopathy. Calcium homeostasis may be altered, 
suggesting a diminished but prolonged increase in intracellul ar 
calcium concentration. Hyperglycemia increases calcium-activated 
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signaling through protein kinase C, which may in turn result in 
cardiac dysfunction.  
 Abnormalities in myofibrillar proteins, such as disturbance in 
troponin I phosphorylation and myosin light chains phosphorylation, 
may also play a role in diabetes-associated impairment of contractile 
function. Advanced glycosylation results in abnormal collagen cross -
linking, which may contribute to decreased compliance and in turn  
to diastolic dysfunction.  
 Several metabolic perturbations may also be responsible factors 
leading to diabetic cardiomyopathy. Glucose contributes 10% to 15% 
of the energy of the heart under normal conditions. However, during 
insulin stimulation, increased workload, and ischemia, the 
metabolism of glucose is increased. Studies using diabetic animal 
models have demonstrated that diabetic hearts have a blunted uptake 
of basal and insulin-stimulated myocardial glucose. The glucose that 
is transported into the diabetic heart is of ten shunted to glycogen 
because of increased fatty acid utilization. Increased fatty acid 
uptake and oxidation itself may decrease cardiac function. 
Ketoacidosis may occur in diabetes. The ketones produced are avidly 
taken up by the diabetic heart and reduce coenzyme A, which in turn 
26 
 
inhibits the citric acid cycle, thereby reducing the energy capability 
of the muscle and resulting in myocardial dysfunction.  
 So the patho-physiology of Diabetic cardiomyopathy has not been 
delineated completely as yet. It is probably multi-factorial. Number mechanisms 
have been proposed. These include 
1)  Metabolic disturbances like hyperglycemia, hyperlipidemia  
2)  Insulin resistance which is the hall mark of type 2 diabetes, 
3)  Microvascular disease complicating diabetes,  
4)  Alterated renin-angiotensin system (RAS) ,  
5)  Autonomic dysfunction of the heart and  
6)  Myocardial fibrosis.  
 Chronic hyperglycemia is thought as the central point in 
pathogenesis of diabetic cardiomyopathy with contributions from 
molecular and metabolic perturbations from within the myocardium and 
also from plasma. The important metabolic alterations in diabetes are 
hyperglycemia, hyperlipidemia and inflammation, each contributing to the 
formation of  reactive oxygen species (ROS) that is postulated to result in 
the end point of most of diabetic complications. Adaptive response to 
these abnormalities do occur but these responses on a chronic course lead 
to myocardial dysfunction and subsequently to heart failure.  
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HYPERGLYCEMIA AND HEART  
 Chronic hyperglycemia results in a number of metabolic and molecular 
changes in the myocardial cells. Increased glucose metabolism due to 
hyperglycemia leads to an increases the oxidative stress by generation of 
reactive oxygen species (ROS) from mitochondria. Overproduction of 
superoxide by the mitochondrial respiratory chain and the consequent oxidative 
stress result in reduction of myocardial contractility and eventually myocyte 
fibrosis. ROS and oxidative stress can cause cellular DNA damage and 
acceleration of cardiomyocyte apoptosis. DNA damage induced by oxidative 
stress also activates poly Adenosyl di-phosphate ribose polymerase (PARP), a 
repair enzyme of DNA. PARP diverts glucose metabolism from its usual 
glycolytic pathway (through inhibition of glyceraldehyde phosphate 
dehydrogenase) into alternative biochemical pathways that result in generation 
of various mediators which causes hyperglycemia leading to cellular injury. 
Activation of the enzyme protein kinase C, increased production of hexosamine 
,sorbitol and advanced glycation end products(AGEs) are the processes through 
which hyperglycemia induces cell death.  
ADVANCED GLYCATION END PRODUCTS AND DBCM 
 Oxidative stress induced by chronic hyperglycemia has been shown to 
increase the AGEs in diabetic subjects. AGEs can covalently crosslink various 
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intra and extracellular proteins that is thought to be a pivotal factor in 
development of complications of diabetes. The collagen and elastin crosslinks 
leads to myocardial stiffness and impairment in cardiac relaxation. AGEs are 
found to induce myocardial damage in both animals and human beings. AGEs 
also indirectly exert their detrimental effect on the myocardium by interacting 
and up-regulating their receptors, including receptors of AGE and galectin-3. 
This results in activation of nuclear transcription factors, like nuclear factor-kB 
(NF-kB). In turn NF-kB dependent genes activate pathways that produce of 
inflammation producing cytokines like Tumour necrosis factor-α and cause 
myocardial damage. NF-kB blockers were found to attenuate mitochondrial 
oxidative stress and protect against cardiac dysfunction in diabetic mice. 
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HEXOSAMINES AND DBCM 
 Chronic hyperglycemia can lead to increased flux of glucose into the 
alternate metabolic pathway known as hexosamine pathway that is implicated in 
many adverse consequences of diabetes. Increased glucose metabolism in the 
hexosamine pathway is associated with disruption of normal cardiomyocyte 
FIGURE 1: MECHANISM OF FORMATION OF ADVANCED GLYCATION END PRODUCTS 
AND DOWNSTREAM PATHWAYS IN DbCM 
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calcium flux linked to reduced sequestration of calcium in the sarcoplasmic 
reticulum. This results in reduction in myocardial performance and impaired 
diastolic relaxation, a possible mechanism for DbCM.  
SORBITOL AND DIASTOLIC DYSFUNCTION 
 Polyol pathway is also activated by chronic hyperglycemia. Sorbitol is 
produced from glucose by the action of the enzyme aldose reductase in the 
presence of nicotinic acid adenine dinucleotide phosphate (NADPH) that is 
oxidized to NADP+. NADPH is a co-factor essential for regeneration of reduced 
glutathione, an important scavenger of ROS in the body, and increased 
utilization of NADPH in the polyol pathway disturbs the redox balance of cells. 
The consequent increase in oxidative stress can lead on to DNA damage and 
cardiomyocyte apoptosis. Sorbitol can also glycate proteins that results in 
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formation of AGEs, which are mediators of tissue injury in diabetes .
 
 
FIGURE 2: SHUNTING OF GLUCOSE INTO HEXOSAMINE AND POLYOL PATHWAY. FORMATION OF 
AGEs, PKC ACTIVATION. ROS FORMATION AND MITOCHONDRIAL DYSFUNCTION 
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FIGURE 3: FINAL COMMON PATHWAY – NFKB ACTIVATION AND INCREASED TRANSCRIPTION 
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FIGURE 4: PROPOSED MECHANISM OF DIABETIC CARDIOMYOPATHY DEVELOPMENT FROM 
HYPERGLYCEMIA 
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LIPID METABOLISM AND THE MYOCARDIUM 
 Increase in strain of cellular oxidation in diabetes leads to lipid 
accumulation in tissues like heart, skeletal muscle, liver. This leads to more 
deposition of lipids in myocardium also termed as Cardiac steatosis, which is 
an important reason for DbCM. Hyperinsulinemia, hyperglycemia, increased 
blood levels of free fatty acids (FFA) in diabetes lead to cardiac steatosis. 
Studies have shown the presence of varying degrees of cardiac steatosis in 
patients with diabetes, impaired glucose tolerance and obesity. Decrease in 
glucose oxidation and increased use of fatty acid for metabolism represents the 
characteristic cardiac energetics modification in type 2 diabetes. Increased levels 
of plasma free fatty acid in patients with diabetes, lead to excessive uptake of 
FFA by cardio myocytes leading on to triglyceride deposition. This exceeds the 
normal capacity of mitochondrial oxidative potential and leads on to a lipotoxic 
injury of heart. Toxic intermediates like ceramide, derived from non-oxidative 
mechanisms, disrupt normal cellular signaling and cause mitochondrial 
dysfunction, cellular damage, apoptosis, and eventually leading on to 
myocardial fibrosis and contractile dysfunction. Intracellular triglyceride 
accumulation alone is relatively inert and unlikely to be the cause for myocardial 
injury. Toxic intermediates like ceramide may be the reason for lipid mediated 
cardiac injury leading to cell death.  
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 Increased FA oxidation in the mitochondria is associated with an increase 
in generation of Reactive oxygen species that oxidizes cytoplasmic lipids into 
lipid peroxides. Reactive oxygen species and lipid peroxides in turn cause 
cellular and mitochondrial damage and uncoupling of mitochondrial oxidative 
metabolism. Consequently, impaired myocardial generation of energy and 
reduced cardiac contractility results. Decreased production of energy leads to an 
altered calcium handling in the mitochondria causing cardiac dysfunction. 
  Cellular apoptosis that results from lipo toxicity is commonly referred to 
as lipo apoptosis. Mechanisms involved in lipoapoptosis are inflammation, 
membrane destabilisation, endoplasmic reticulum stress, toxicity due palmitate, 
diacyl glycerol (DAG) and ceramide. Structural damage and myocardial fibrosis 
are the results of lipoapoptosis that compromise the cardiac function. Elevated 
levels of plasma FFA also induce cellular insulin resistance by various 
mechanisms. These include protein kinase C activation, and activation of 
peroxisome proliferator-activated receptor-gamma and α (PPAR-γ and PPAR-
α).  
 PKC is a family of several isoenzymes that regulates various complex 
cellular metabolic pathways, and plays an important role in development of 
insulin resistance. Similarly, the activation of PPAR-γ and PPAR-α also results 
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in hyperinsulinemia and insulin resistance, mediated through different complex 
mechanisms. 
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FIGURE 5: PROPOSED MECHANISM OF DIABETIC CARDIOMYOPATHY DEVELOPMENT FROM 
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ROLE OF HYPERINSULINEMIA AND INSULIN RESISTANCE 
 Hyperinsulinemia and insulin resistance are the characteristic pathological 
abnormalities in T2DM and prediabetic states. Hyperinsulinemia results in 
cardiomyocyte hypertrophy by various mechanisms. Brain natriuretic peptide 
(BNP), a biomolecule which the ventricles release in response to stretch is 
increased in patients with heart failure. BNP is also an important molecular 
marker of cardiac hypertrophy. BNP gene expression was found to be 
significantly higher in animal models with hyperinsulinemia and insulin 
resistance. Increase in left ventricular mass and left ventricular hypertrophy is 
found in these animal models. Recently, BNP has emerged as a useful biomarker 
for screening subclinical ventricular diastolic dysfunction in patients with 
uncontrolled diabetes. 
  Hypertrophy of cardiac myocytes in diabetes was found to be regulated at 
the transcriptional level. Various genetic and epigenetic alterations resulting 
from hyperinsulinemia, leads on to activation of multiple transcription factors 
that modulate cellular and extracellular protein expression. Activation of such 
transcription factors have been shown to result in cardiomyocyte hypertrophy 
and deposition of extracellular matrix proteins causing focal cardiac fibrosis in 
diabetes. 
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CONTRIBUTION FROM MICROVASCULAR ISCHEMIA 
 The pathological hallmark of diabetes-related vascular complications is 
damage to the microvasculature throughout the body. Classical examples of 
microvascular complications are diabetic retinopathy, nephropathy  and 
neuropathy. Hyperglycemia confounded by other factors such as hypertension, 
lipid abnormalities and smoking impose oxidative stress on the vascular 
endothelium that leads on to endothelial dysfunction, the earliest abnormality in 
patients with diabetes. Nitric oxide (an endothelium-derived vasodilatory factor) 
production in relation to vascular stretch is also reduced due to down regulation 
of endothelial nitric oxide synthase enzyme in diabetes. Hyaline change of the 
medial layers of arterioles and reduction of capillary length density throughout 
the cardiac circulation is seen in diabetics. The microvascular diasease resulting 
in reduced blood supply affects the vasa vasorum in diabetes, damages the small 
and medium arterioles of the diabetic heart. Capillary basement membrane, 
microaneurysms of small vessels, perivascular fibrosis and interstitial changes 
are the other vascular abnormalities causing cardiac microvascular ischemia in 
diabetes. Ischemia contributes to myocardial stiffness, fibrosis and cardiac 
dysfunction in DbCM.  
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ROLE OF RENIN ANGIOTENSIN SYSTEM 
 Recent evidence from animal and human experiments have demonstrated 
significant role of RAS in diabetes induced cardiac dysfunction. The major 
components of RAS, i.e., renin, angiotensinogen, angiotensin converting 
enzyme (ACE), angiotensin II(AGT II) receptors are expressed in the heart. 
Intra cardiac RAS is activated by hyperglycemia and has varying effects on the 
myocardium. When compared to non diabetic, patients with diabetes were found 
to express higher levels of intracellular AGT II. 
 Cytoplasmic AGT II has been shown to induce cell growth in animal 
models. AGT II may cause myocyte hypertrophy and fibroblast proliferation. In 
addition to above effects inflammation, oxidative stress and aldosterone, may 
also contribute to the deleterious effects of AGT II on the heart producing 
myocardial damage in diabetes.  
CARDIAC AUTONOMIC NEUROPATHY AND DBCM 
 Cardiac autonomic neuropathy (CAN) complicates long standing 
diabetes that causes abnormal vascular hemodynamics and control of heart rate. 
The prevalence of varying degrees of CAN may be as high as 60% in 
individuals with prolonged history of diabetes. CAN affects blood flow in the 
coronary vasculature and also alters the contractile function of the myocardium. 
Patients with CAN were found to have a reduction in the vascular elasticity and 
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an increased systemic vascular resistance due to abnormal sympathetictone. 
Reduction in myocardial perfusion reserve also was shown by other 
investigators. This may partly explain the ventricular dysfunction associated 
with diabetic CAN. Correlation between the severity of CAN and the prevalence 
of diastolic dysfunction also have been demonstrated. Alterations in the 
myocardial contractility responses in relation to stress is seen in patients with 
diabetic CAN, and even in those with normal ventricular function at rest, 
exerciseinduced myocardial dysfunction have been demonstrated. 
STRUCTURAL AND FUNCTIONAL ALTERATIONS IN DBCM 
 Significant functional and anatomical changes occurs in diabetic 
cardiomyopathy. Changes like formation of Advanced Glycation End products, 
reactive oxygen species, microvascular ischemia of vaso vasorum,imapaired 
compliance cause myocardial contractile dysfunction. Later on changes like 
perivascular fibrosis, interstitial fibrosis and myocardial hypertrophy occur. 
Earliest change in DbCM is an altered diastolic function which is followed by a 
systolic dysfunction at later stages. Diastolic dysfunction is characterized by 
impaired relaxation of the ventricular musculature during diastole with a 
resultant increase in left ventricular end diastolic filling pressure and diastolic 
heart failure. When systolic dysfunction supervenes the cardiac output 
diminishes progressively with the severityof disease.  
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CARDIAC REMODELING IN DBCM 
 DbCM results from the structural, functional and regulatory remodeling of 
the heart induced by diabetes mellitus. Different stages of remodeling has been 
proposed: the early stage, middle stage and the late stage.   
 The early stage is usually asymptomatic with myocardial changes mostly 
at the molecular level. Ventricular hypertrophy and diastolic dysfunction with a 
normal LVEF are the only gross abnormalities demonstrable at this stage.  
 The middle stage of DbCM is characterized by progressive 
cardiomyocyte hypertrophy and myocyte fibrosis. Increasing ventricular wall 
thickness and muscle mass at this stage result in worsening of the diastolic 
dysfunction and the development of mild systolic dysfunction.  
 Further progression of the disease in the late stage is associated with 
abnormalities like CAN, microvascular/macrovascular CAD, hypertension, and 
overt diastolic and systolic dysfunction.  
INTERACTION WITH COEXISTENT HYPERTENSION AND CAD 
The diagnosis of DbCM is made only when co existent coronary artery heart 
disease and hypertension are excluded. However, when both hypertension and 
CAD complicate the already existing diastolic dysfunction in a diabetic patient 
there is rapidity in progression to advanced stages of heart failure. Diagnostic 
evaluation may be complicated by clinically silent coronary artery disease. 
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Coexisting hypertension was found in upto 35% of Type1 Diabetes Mellitus and 
upto 75% with type 2 diabetes mellitus. Cardiac dysfunction was shown to be 
worsened by hypertension in animal models of DbCM. Also the presence of 
hypertension has been found to be independently associated with diastolic 
dysfunction in diabetic patients. Similarly, myocardial structural abnormalities 
were found to occur in diabetic patients with CAD.  
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ASSESSMENT OF DIASTOLIC FUNCTION  
 Assessment of diastolic function should be an integral part of an 
evaluation of cardiac function because about 50% of patients with heart failure 
have preserved LVEF. Assessment of diastolic function requires an 
understanding of diastology and various means to evaluate diastolic function. 
Currently, echocardiography is the best non invasive way to evaluate diastolic 
function and to estimate filling pressures. M-mode, two-dimensional, and 
Doppler (blood flow, tissue, and color) echocardiography are all helpful in 
evaluating diastolic function. Recently, the ASE and the European Association 
of Echocardiography (EAE) published a guideline for assessment of diastolic 
function by echocardiography. The following steps will ensure comprehensive 
assessment of diastolic function and the identification of heart failure related to 
diastolic dysfunction:  
   
1     Look for M-mode and two-dimensional echocardiographic evidence of 
diastolic dysfunction. Abnormal myocardial relaxation, an integral part of 
diastolic dysfunction, decreases the slope (in M-mode) and mitral annulus 
motion of early diastolic filling and increases LA size. LV wall thicknesses 
is usually but not necessarily increased. 
   2     Mitral inflow velocities reflect the transmitral pressure gradient, which is 
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usually characteristic of various stages of diastolic dysfunction. 
Assessment of ventricular compliance is possible from the configuration 
(velocities and flow duration) of mitral inflow velocities. Pulmonary vein 
flow velocities are also helpful. 
   
3     Myocardial relaxation by TDI can be evaluated. Mitral annulus velocity 
(e′) during early diastole correlates reasonably well with the status of 
myocardial relaxation (tau). 
   
4     Mitral inflow velocities (E and A), e′, propagation velocity at inflow of 
mitral valve, and their combination can estimate LV filling pressure in 
diastole with exercise and at rest. 
   
5     These steps allow diagnosis of diastolic heart failure and separation of 
myocardial diastolic heart failure from pericardial diastolic heart failure  
 LV diastolic filling consists of a series of events that are affected by 
numerous factors, including myocardial relaxation, compliance, cardiac rhythm, 
and pericardial compliance. Normal diastolic function ensures adequate filling 
of the ventricles during rest and exercise without an abnormal increase in 
diastolic pressure or pulmonary venous congestion. Early rapid diastolic filling 
occurs when Left Ventricular pressure falls below corresponding atrial pressure, 
and mitral valve opens. The principal determinant of early diastolic filling is the 
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elastic recoil caused by normal relaxation of the left ventricle. Normally, 75% to 
80% of LV filling occurs during this phase. During early diastolic filling, LV 
pressure continues to decrease until completion of myocardial relaxation 
(normally about 100 milliseconds) before rising after reaching minimal pressure; 
this loss of positive driving force results in the deceleration of mitral inflow. 
Later, atrial contraction produces a positive pressure gradient for transmitral 
inflow, accounting for 20% to 25% of LV filling in normal subjects. 
 The proportion of LV filling during the early and late diastolic phases 
depends on elastic recoil (suction), rate of myocardial relaxation, chamber 
compliance, LA pressure, and heart rate. The LV filling pattern is the result of 
the transmitral pressure gradient produced by these various factors.  
The transmitral pressure gradient or the relationship between LA and 
LV pressures is accurately reflected by mitral inflow Doppler velocities. 
Diastolic filling is usually classified initially on the basis of the peak mitral flow 
velocity of the early rapid filling wave (E), peak velocity of the late filling wave 
caused by atrial contraction (A), E/A ratio, and deceleration time (DT), which is 
the time interval for the peak E velocity to reach zero baseline . 
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FIGURE 8: ECHO CARDIO GRAPHIC WINDOW TO SHOW THE E AND A WAVE 
FIGURE 9: ECHO CARDIO GRAPHIC WINDOW TO SHOW THE DECERATION TIME 
(DT) 
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With myocardial relaxation, the LV cavity elongates, expands laterally, 
and rotates. The longitudinal motion of the mitral annulus has been shown to 
correlate with the rate of myocardial relaxation. The velocity of the mitral 
annulus can be recorded by TDI, which has become an essential part of 
evaluation of diastolic function by echocardiography. Radial and circumferential 
function can also be assessed with speckle tracking strain imaging. 
Comprehensive assessment of diastolic filling and estimation of filling 
pressures by echocardiography require TDI, pulmonary vein Doppler, hepatic 
vein Doppler, and color M-mode of mitral inflow for propagation velocity—
sometimes with an alteration in a loading condition .The Valsalva maneuver is 
used most frequently to decrease venous return by increasing intrathoracic 
pressure 
Grading of Diastolic Dysfunction (or Diastolic Filling Pattern)  
 
The grading of the diastolic filling pattern (or diastolic dysfunction) is 
based on several parameters. In many cardiac disease , the initial 
abnormality in diastole is impaired relaxation. With further 
progression of disease and a mild to moderate increase in LA pressure, 
the dysfunction shows  a normal filling pattern (pseudonormalized). 
With further decreased Left Ventricular compliance and increased Left 
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Atrial pressure, diastolic filling becomes restrictive. Most patients with 
restrictive filling are symptomatic and have a poor prognosis unless the 
restrictive filling can be reversed by treatment. However, restrictive 
filling may be irreversible and represent the end stage of diastolic heart 
failure. Therefore, diastolic dysfunction can be graded according to the 
diastolic filling pattern. 
 
A grade 1 diastolic filling pattern usually implies a normal filling 
pressure despite a background of impaired myocardial relaxation. 
However, in patients with a marked relaxation abnormality, as in 
HCM, the filling pressure can still be elevated with grade 1 mitral 
inflow velocity pattern (E/A ratio <1.0 and DT >240 milliseconds).  
 
   
NORMAL DIASTOLIC FILLING PATTERN  
 
In healthy subjects, the Left Ventricular recoil elasticity is vigorous 
because of normally relaxing myocardium; therefore, most filling is 
completed during early diastole. Thus, the E/A ratio is usually 1.5 or 
higher, DT is 160 to 240 milliseconds (septal), e′ is 10 cm/sec or higher, 
E/e′ is less than 8, and Vp is 50 cm/sec or higher.  
With normal myocardial relaxation, the longitudinal mitral annulus 
diastolic velocity pattern mirrors that of normal mitral inflow: early diastolic 
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velocity (e′) is higher than late diastolic velocity (a′). Lateral annulus velocity is 
always higher (normal, >15 cm/sec) than septal e′. Thus, e′ increases with 
exercise in healthy subjects so that E/e′ is similar at rest and with exercise 
(usually <8). With aging, there is a gradual decrease in the rate of myocardial 
relaxation as well as in elastic recoil, resulting in slower decline of LV pressure, 
and filling becomes slower, producing a diastolic function pattern similar to 
grade 1 dysfunction. At roughly the age of 65 years, E velocity approaches A 
velocity, and in persons older than 70 years, the E/A ratio is usually less than 
1.0. The reversal of e′/a′ occurs about 10 to 15 years earlier than that of E/A. 
 
TABLE 2: REFERENCE RANGES FOR DIASTOLIC FUNCTION PARAMETERS BY AGE* 
QUOTED FROM BRAUNWALD’S HEART DISEASE-9th EDITION 
PARAMETER 
Age Groups (yr) 
45-49 50-54 55-59 60-64 65-69 ≥70 
Mitral inflow 
 E, m/sec 0.7 (0.5-0.9) 0.6 (0.5-0.9) 0.7 (0.5-0.9) 0.7 (0.5-0.9) 0.6 (0.4-0.8) 0.6 (0.4-1.0) 
 A, m/sec 0.5 (0.3-0.7) 0.5 (0.4-0.8) 0.6 (0.4-0.9) 0.6 (0.4-0.9) 0.7 (0.4-1.0) 0.8 (0.5-1.1) 
 E/A 1.3 (1.0-2.0) 1.2 (0.8-2.0) 1.2 (0.7-1.8) 1.0 (0.7-1.6) 1.00 (0.6-1.50) 0.8 (0.6-1.3) 
 E/(A-E at A) 
1.50 (1.0-
2.67) 
1.40 (1.0-
2.33) 
1.29 (0.83-
2.25) 
1.20 (0.83-2.0) 
1.00 (0.75-
1.67) 
1.00 (0.67-
1.60) 
 DT, msec 208 (180-258) 217 (178-266) 210 (183-187) 222 (180-282) 227 (188-298) 242 (188-320) 
 Adur, msec 140 (122-170) 147 (130-172) 147 (127-173) 147 (129-172) 150 (122-180) 150 (128-183) 
Pulmonary vein flow 
 PS, m/sec 
0.60 (0.40-
0.80) 
0.60 (0.40-
0.80) 
0.60 (0.40-
0.80) 
0.60 (0.40-
0.80) 
0.60 (0.50-
0.80) 
0.60 (0.40-
0.80) 
 PD, m/sec 
0.40 (0.30-
0.60) 
0.40 (0.30-
0.60) 
0.40 (0.30-
0.60) 
0.40 (0.30-
0.60) 
0.40 (0.30-
0.60) 
0.40 (0.30-
0.60) 
 PS/PD 
1.25 (0.86-
2.00) 
1.40 (1.00-
2.00) 
1.40 (1.00-
2.00) 
1.50 (1.00-
2.25) 
1.60 (1.00-
2.50) 
1.67 (1.00-
2.50) 
PVARdur, msec 118 (100-140) 122 (103-142) 123 (105-157) 123 (103-160) 127 (110-152) 130 (112-170) 
PVARdur − Adur, −25.0 (−53.3- −25.0 (−51.7- −21.6 (−50.0- −23.3 (−51.7- −21.7 (−55.0- −22.3 (−51.7-
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PARAMETER 
Age Groups (yr) 
45-49 50-54 55-59 60-64 65-69 ≥70 
msec 0) 0) 11.7) 13.4) 12.5) 31.6) 
TDI, mitral annulus 
 Septal 
 E′S, m/sec 
0.10 (0.07-
0.14) 
0.09 (0.06-
0.14) 
0.09 (0.05-
0.12) 
0.09 (0.06-
0.13) 
0.08 (0.05-
0.11) 
0.07 (0.05-
0.11) 
 A′S, m/sec 
0.10 (0.07-
0.14) 
0.10 (0.08-
0.14) 
0.11 (0.08-
0.15) 
0.11 (0.09-
0.15) 
0.11 (0.09-
0.15) 
0.11 (0.09-
0.15) 
 E/E′S 
6.67 (4.62-
11.25) 
7.00 (4.55-
11.67) 
7.78 (4.62-
13.33) 
7.64 (5.0-12.0) 
8.57 (5.45-
13.33) 
8.57 (4.55-
16.67) 
 Lateral 
 E′L, m/sec 
0.13 (0.09-
0.17) 
0.12 (0.08-
0.16) 
0.11 (0.07-
0.15) 
0.10 (0.07-
0.15) 
0.09 (0.07-
0.12) 
0.08 (0.05-
0.11) 
 A′L, m/sec 
0.11 (0.07-
0.16) 
0.11 (0.07-
0.15) 
0.11 (0.08-
0.16) 
0.12 (0.08-
0.17) 
0.12 (0.09-
0.16) 
0.12 (0.08-
0.18) 
 E/E′L 
5.38 (3.75-
7.78) 
5.45 (3.75-
8.89) 
6.0 (3.85-10.0) 
6.67 (4.62-
8.89) 
7.0 (4.17-
11.25) 
7.78 (5.0-14.0) 
Valsalva maneuver 
 VS E/A 
1.00 (0.60-
1.33) 
1.00 (0.57-
1.33) 
0.80 (0.44-
1.25) 
0.71 (0.43-
1.20) 
0.60 (0.40-
1.00) 
0.57 (0.30-
1.00) 
 VS E/(A-E at A) 
1.33 (0.80-
2.50) 
1.25 (0.67-
3.00) 
1.00 (0.60-
2.50) 
1.00 (0.50-
2.00) 
0.75 (0.50-
1.67) 
0.71 (0.33-
1.50) 
 ΔE/A 0.37 (0-1.0) 
0.40 (−0.05-
1.0) 
0.37 (0-1.0) 
0.36 (−0.04-
0.80) 
0.31 (0-0.64) 
0.29 (−0.04-
0.70) 
 ΔE/(A-E at A) 0.0 (−1.3-1.0) 
0.07 (−1.33-
0.75) 
0.17 (−1.0-
0.77) 
0.13 (−0.83-
0.75) 
0.17 (−0.58-
0.57) 
0.17 (−0.75-
0.63) 
Index of myocardial performance 
 LIMP 
0.30 (0.10-
0.50) 
0.30 (0.20-
0.60) 
0.30 (0.20-
0.60) 
0.40 (0.20-
0.60) 
0.40 (0.20-
0.60) 
0.40 (0.20-
0.60) 
 
 
Modified from Munagala VK, Jacobsen SJ, Mahoney DW, et al: Association of newer diastolic 
function parameters with age in healthy subjects: A population-based study. J Am Soc 
Echocardiogr 16:1049, 2003. 
A = late diastolic mitral flow velocity; Adur = duration of late mitral flow; A′L = lateral mitral 
annulus velocity with atrial contraction; A′S = late diastolic lateral annular velocity; DT = 
deceleration time of early diastolic mitral flow; E = early diastolic mitral flow velocity; E′L = 
early diastolic lateral annular velocity; E′s = early diastolic septal annular velocity; ΔE/A = 
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change in E/A with Valsalva; ΔE/A-E = change in E/A-E at A with Valsalva; LIMP = left 
ventricular index of myocardial performance; PD = pulmonary vein diastolic flow velocity; PS 
= pulmonary vein systolic flow velocity; PVARdur = duration of pulmonary vein atrial flow 
reversal; TDI = tissue Doppler imaging; VS = peak Valsalva. 
 
*
 Data are median (5th and 95th percentiles). 
 
Grade 1 Diastolic Dysfunction or Mild Diastolic Dysfunction  
 
An early abnormality of diastolic filling is abnormal myocardial 
relaxation. Typical cardiac conditions that produce abnormal 
relaxation are LV hypertrophy, HCM, and myocardial ischemia or 
infarction as well as aging. During this stage of diastolic dysfunction, 
an adequate diastolic filling period is critical to maintain normal filling 
without increasing filling pressure. As long as LA pressure remains 
normal, the pressure crossover between the left ventricle and left 
atrium occurs late, and the early transmitral pressure gradient is 
decreased. Consequently, the isovolumic relaxation time (IVRT) is 
prolonged. Mitral E velocity is decreased and A velocity is increased, 
producing an E/A ratio of less than 1, with prolonged DT. Pulmonary 
vein diastolic forward flow velocity parallels mitral E velocity and is 
also decreased with compensatory increased flow in systole. The 
duration and velocity of pulmonary vein atrial flow reversal are usually 
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normal, but they may be increased if atrial compliance decreases or LV 
end-diastolic pressure (LVEDP) is high. The e′ and mitral flow 
propagation velocity are reduced, usually less than 7 cm/sec (at the 
septal annulus) and less than 50 cm/sec, respectively. In most patients 
with the described mitral inflow velocity pattern, diastolic filling 
pressure is not increased and the E/e′ ratio is 8 or higher. In a subgroup 
of patients, E/e′ ratio is higher than 15, with an E/A ratio less than 1. 
This pattern has been designated grade 1a diastolic dysfunction to 
emphasize that filling pressure is increased while there is a typical 
grade 1 mitral inflow velocity pattern. 
 
Grade 2 Diastolic Dysfunction or Moderate Diastolic Dysfunction  
 
 
This stage is otherwise referred to as the pseudonormalized mitral flow 
filling pattern, and it indicates a moderate stage of diastolic 
dysfunction. With worsening diastolic function, the mitral inflow 
pattern resembles a normal diastolic filling pattern, i.e, an E/A ratio of 
1 to 1.5 and normal Deceleration Time of 160 to 240 milliseconds. 
This is due to a moderately increased LA pressure over and above the 
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delayed myocardial relaxation. There are several ways to differentiate 
the pseudonormal pattern from a true normal pattern in patients with 
grade 2 dysfunction: 
   
1     The e′ is usually less than 7 because of impaired myocardial relaxation. 
 
   
2     Frequently, there is mid-diastolic flow because the myocardial relaxation is 
markedly impaired. 
 
   
3     A decrease in preload, by asking the patient to sit or to perform the 
Valsalva maneuver, the underlying impaired relaxation of the left ventricle 
may be unmasked, decreasing the E/A ratio by more than 0.5. An increase 
in A velocity with the Valsalva maneuver, is a positive sign. 
   
4     Normal-appearing mitral inflow may occur in the setting of systolic 
dysfunction or increased wall thickness because impaired relaxation is 
expected as the baseline diastolic function without increased filling 
pressure in those situations, and a normal E/A ratio suggests that increased 
LA pressure is masking the abnormal relaxation. 
       
 
   
5     Colour M-mode of mitral inflow shows decreased rate of flow propagation 
(<45 cm/sec).Although this is a less reliable in patients with normal LV 
cavity size. 
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Grade 3-4 Diastolic Dysfunction or Severe Diastolic Dysfunction  
 
Severe diastolic dysfunction is termed as restrictive filling or 
restrictive physiology and can be seen in any cardiac abnormality or in 
a combination of abnormalities that results in decreased Left 
Ventricular compliance and increased Left atrial pressure. 
Therefore, the characteristics of restrictive filling with severe diastolic 
dysfunction include  
a)Increased E velocity, 
b)Decreased A velocity (markedly less than E)  
c)E/A ratio > 2, and  
d)Shortened Deceleration Time of  <160 milliseconds and  
e)Iso-Volumetric Relaxation Time  <70 milliseconds. 
Pulmonary venous systolic forward flow velocity is decreased because 
of increased Left Atrial pressure and decreased Left Atrial compliance. 
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Since the myocardial relaxation is impaired in heart with a restrictive 
filling pattern, mitral annulus velocity (Ea) is decreased (<7 cm/sec). 
The E/e′ ratio is usually more than 15. In case of normal systolic 
function and small left ventricular cavity the flow propagation velocity 
may not be reduced. The Valsalva maneuver may reverse back the 
restrictive filling pattern from grade 3 to a grade 1 to 2 pattern, 
indicating the reversible high filling pressure (grade 3 diastolic filling). 
However, if the restrictive filling pattern does not change with the 
Valsalva maneuver, reversibility cannot be excluded because the 
Valsalva maneuver may not alone be adequate or filling pressure is 
very high to be changed by the Valsalva maneuver. 
 
   
58 
 
 
 
 
 
 
FIGURE 9: ECHO CARDIO GRAPHIC GRADING OF DIASTOLIC DYSFUCNTION 
FIGURE 10: ECHO CARDIO GRAPHIC TISSUE DOPPLER IMAGING AND M-MODE FEATURES -VARIOUS 
STAGES IN DIASTOLIC DYSFUNCTION 
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CLINICAL APPLICATIONS OF DIASTOLIC FUNCTION ASSESSMENT  
Assessment of diastolic function echocardiographically has the following 
clinical applications  
   
1     Estimation of filling pressures with exercise and at rest. In patients with 
reduced Left Ventricular systolic function i.e., Left Ventricle Ejection 
Fraction <35%, mitral inflow E/A ratio of 1.5 or more and Deceleration 
Time of 140 milliseconds or more indicate increased filling pressures. 
FIGURE 10: ECHO CARDIO GRAPHIC TISSUE DOPPLER IMAGING AND M-MODE 
FEATURES- VARIOUS STAGES- DIASTOLIC DYSFUNCTION 
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However, these parameters do not have a good correlation with filling 
pressure in patients with normal LVEF and diastolic heart failure. For all 
degrees of LVEF,  the parameter E/e′ is the best find out pressures of 
filling ; pulmonary capillary wedge pressure (PCWP) is 20 mm Hg or more 
if E/e′ is 15 or higher, and PCWP is normal if E/e′ is less than 8. When E/e′ 
is 8 or higher but less than 15, duration of pulmonary vein flow, Valsalva 
maneuver can help estimate PCWP. In an important subset of patients with 
diastolic dysfunction, at rest Pulmonary Capillary Wedge Pressure is 
normal and casuses effort dyspnoea because it is increased only on effort. 
Mitral inflow and annulus velocity can be used to measure pulmonary 
capillary wedge pressure. Filling pressures do not rise with exertion when 
the diastolic function is normal. Exertion induced high pressues during 
filling occurs mainly when the relaxation of myocardium is impaired. In 
such patients cardiac output increases with associated increase in filling 
pressure. Because of this, mitral E velocity increases and annulus E 
velocity does not increase , leading to increased E/e′ ratio. E/e′ correlates 
well with simultaneously measured PCWP with exercise as well as during 
resting stage, and a ratio higher than 15 indicates PCWP greater than 
20 mm Hg with exercise. 
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2     Diagnosis of diastolic heart failure, cardiomyopathies, and constrictive 
pericarditis. Knowledge of the diastolic filling pattern and filling pressures 
allows the detection of cardiac diseases that are frequently missed or not 
suspected clinically, especially when the LVEF is normal. Patients with 
diastolic heart failure and normal LVEF have a large LA volume and 
evidence of impaired relaxation as well as increased filling pressure. There 
are several reports that TDI of myocardial relaxation can diagnose various 
forms of cardiomyopathy (HCM, Fabry disease, and amyloidosis) even 
before frank phenotypic manifestation.The detection of constrictive 
pericarditis has been made much easier with the use of echocardiographic 
diastolic parameters and TDI. 
   
3     Prognosis. Diastolic echocardiographic parameters, E, E/A, DT, E/e′, and 
LA volume, have been found to be powerful prognostic indicators for 
various conditions. Even in asymptomatic patients, the presence of 
diastolic dysfunction portends a poor clinical outcome. 
 
Although diastolic filling is affected by various factors, the direction of 
its change or progression is predictable in patients with known heart 
disease. Therefore, assessment of the diastolic filling pattern allows 
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LV filling pressures and LV compliance and relaxation to be estimated 
and understood so that optimal treatment strategies can be offered to 
symptomatic patients with diastolic dysfunction. 
 
 
 
FIGURE 11: A PRACTICAL APPROACH TO CLASSIFICATION OF DIASTOLIC DYSFUNCTION 
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MATERIALS AND METHODS  
 
 This study was conducted in Tirunelveli medical college hospital over a 
period of 12 months. Patients were recruited to the study from medical OPD and 
DIABETIC OPD. A total of about 120 patients were selected and 20 of them 
were excluded as per exclusion criteria used. The remaining 100 patients were 
included in the study. Among them 50 patients were diabetics and 50 were non 
diabetic controls. Informed consent was obtained from all patients. Diastolic 
dysfunction was measured with standard echocardiographic parameters and the 
results were computed with corresponding variables of the patients. For the 
purpose of the study it was hypothesized that the diastolic dysfunction occurring 
in diabetes would worsen with age of patients, duration of diabetes, hba1c 
values, obesity indices. 
Study Design: 
A case control study done prospectively at the tertiary care hospital over 1 year. 
Sample size- 100 
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Inclusion Criteria 
1) Asymptomatic type 2 diabetes patients who presented to the medical opd 
and diabetic opd 
2) Healthy individuals between the age of 20-60 
Exclusion criteria 
 1) Patients with evidence of previous coronary artery heart disease- 
determined by 
  i)Previous history of angina 
  ii)Electrocardiographic changes in the form of ST elevation/ST  
         depression/significant q  waves 
  iii)Echo cardiographic evidence of regional wall motion 
abnormalities 
  iv)Treadmill testing with positive testing for ischemia 
 2) Patients with evidence of valvular heart disease as confirmed by 
standard        echocardiographic observation 
 3) Patients with evidence of systemic hypetersion- determined by 
  i)History of systemic hypertension 
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  ii)History of drug intake for the hypertension 
  iii)Evidence of left ventricular hypertrophy with characteristics ST-
T        changes on the electrocardiogram 
4) Patients with poor trans thoracic window 
METHODOLOGY  
 
For all the 100 cases admitted ,detailed clinical examination and history 
regarding diabetes, hypertension, coronary heart disease, valvular heart disease 
were obtained.  
Patients’ anthropometric measurements were done. BMI and Waist hip ratio 
were calculated. 
Examination for autonomic dysfunction was done. 
Fundus examination for diabetic retinopathy was done. 
Investigations like Blood sugar ,ECG ,HBA1C,lipid profile were obtained. 
Echocardiographic assessement of both systolic and diastolic dysfunction were 
done. 
DEFINING THE STUDY POPULATION  
 Diabetes Mellitus was defined as the presence of a fasting plasma glucose 
level greater than 126 mg/dl or a 2 hour post prandial plasma glucose level 
greater than 200 mg/dl or an HBA1 C level greater than 6.5%. 
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Patients with a known history of diabetes with duration of more than 5 years and 
on treatment were selected as cases for the purpose of studying diastolic 
dysfunction. Careful history was taken to rule out exclusion criteria if present. 
 An equal number of healthy individuals with no history of prior diabetes 
were chosen. Blood sugar levels and HBA1C levels were obtained. Patients’ age 
was between 20-60 yrs and they were selected randomly. 
GLYCATED HEMOGLOBIN (HBA1C) 
  Hb A1c is formed by non-enzymatic glycation of  hemoglobin's by 
plasma glucose. HbA1c is a measure of the beta-N-1-deoxy fructosyl component 
of hemoglobin. Normal levels of plasma glucose produce a normal amount of 
glycated hemoglobin. If the average plasma glucose increases, the fraction of 
glycated hemoglobin increases. Hb A1c is a marker for average plasma glucose 
levels over the previous 3 months prior to the measurement as this is the half life 
of RBCs. 
In diabetes mellitus, increased glycated hemoglobin, indicates  poorer 
control of blood glucose levels, have been associated with micro vascular 
complications like cardiovascular disease, nephropathy, and retinopathy.   
Huisman and Meyering in 1958 first separated HbA1c from other forms 
of hemoglobin by using a chromatographic column.  Bookchin and Gallop in 
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1968 first characterized it as a glycoprotein. Samuel Rahbar et al described the 
increase of HbA1c in diabetes in 1969. Bunn and his coworkers described the 
reactions leading to its formation in 1975. 
Blood sugar and HBA1C levels were measured using standard 
biochemical tests. 
DIABETIC RETINOPATHY 
 Retinopathy is hall mark of microvascular complications of in diabetes 
mellitus. The exact pathophysiology though remains unclear. Diabetic 
retinopathy is one of the common causes of preventable blindness. Patients are 
usually asymptomatic in the early stage of the disease but as the disease 
progresses there is plethora of symptoms like blurred vision, floating particles in 
the visual field, visual distortion, decrease in visual acuity progressively. Micro 
aneurysms, flame shaped haemorrhages, dot-blot haemorrhages, cotton wool 
spots, retinal edema, hard exudates, venous beading, intra retinal microvascular 
abnormalities and macular edema are some of the signs in diabetic retinopathy. 
 Microaneurysms are the earliest clinical sign of diabetic retinopathy. These are 
capillary wall outpouching secondary to pericyte loss which are seen as tiny, 
red dots in the superficial layers of retina 
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 Flame-shaped hemorrhages are splinter hemorrhages found in the superficial 
nerve fiber layer 
 Dot and blot hemorrhages occur in the deep layers of retina like the inner 
nuclear and plexiform layers due to rupture of the micro aneurysms. When the 
are small they look similar to micro anusrysms. 
 Cotton-wool spots are whitish spots which are at times surrounded by 
microaneurysms . These occur due occlusion of precapillary arterioles that 
leads on to infarction of the nerve fiber layer. 
 Retinal edema and hard exudates are due to the breakdown of the blood-retina 
barrier. This break in blood retina barrier leads to leak in serum lipids and 
proteins which lead to interstitial edema that subsequently become hard 
exudates. 
 Venous loops and venous beading are signs of progression from non 
proliferative retinopathy to proliferative retinopathy. Due to increasing retinal 
ischemia there is poor perfusion of nearby retinal layers leading to venous 
abnormalities.. 
 Intraretinal microvascular abnormalities (IRMA) are found in the retina layers 
with near absent perfusion. Its due to capillary remodeling with no associated 
proliferative changes.  
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Diabetic retinopathy is usually classified as non proliferative diabetic 
retinopathy and proliferative diabetic retinopathy. 
Nonproliferative diabetic retinopathy (NPDR) 
It may be of 3 stages 
 Mild NPDR is presence of at least 1 microaneurysm. 
 In Moderate NPDR characterized by microaneurysms, retinal hemorrhages and 
hard exudates. 
 Severe NPDR includes microaneurysms and hemorrhages in all 4 quadrants, 
venous beading in at least 2 quadrants and intraretinal microvascular (IRMA) 
abnormalities in at least 1 quadrant. 
Proliferative diabetic retinopathy 
It includes the following (PDR) 
 Neovascularization which is pathognomic of PDR 
 Preretinal hemorrhage which are pockets of blood  collected between the 
posterior hyaloids membrane and retina. 
 Vitreous Hemorrhage which appear as a diffuse haze or as clumps of blood 
clots within the gel 
 Fibrovascular tissue proliferation  
 Traction retinal detachments  
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 Macular edema 
The evaluation of diabetic retinopathy is done clinically using fundus 
examination after dilation with tropicamide 1 % eye drops. Investigations that 
are helpful in evaluation are fundus flourescien angiography (FFA), B-scan 
ultrsonography and optical coherence tomography (OCT). 
 
 
 
CARDIAC AUTONOMIC NEUROPATHY 
 Cardiac Autonomic Neuropathy causes significant mortality and 
morbidity in diabetics. It results in very high risk of arrhythmias and sudden 
cardiac death (SCD) probably due to silent myocardial infarctions. 
FIGURE 1: FUNDUS PICTURE OF BACKFROUND 
RETINOPATHY WITH FEATURES OF MICROANEURYSMS 
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 CAN results from interaction between various factors like blood pressure 
both systolic and diastolic, glycemic control, duration of disease. Hyperglycemia 
produces advanced glycation end products, activation of polyol pathway, 
activation protein kinase C. These changes result in increased ROS production. 
The microvascular ischemia of vaso vasarum and free radical damage are 
proposed as the cause for nerve cell damage in diabetes leading on to autonomic 
neuropathy. 
 Long standing hyperglycemia causes dying back neuropathy. The longest 
nerve of the body Vagus supplies parasympathetic innervations to heart. Since 
the neuropathy affects the nerves with long course, the first manifestation of 
diabetic autonomic neuropathy is parasympathetic denervation. There is an 
associated increase in sympathetic tone. As the disease progresses there is 
abnormal nor adrenaline signalling and its metabolism is altered within heart in 
diabetics. Co- existent free radical injury, mitochondrial stress, calcium 
dependent cellular destruction may contribute to myocyte loss and the high risk 
of arrhythmias and sudden cardiac death. 
 The clinical symptom in cardiac autonomic neuropathy is exercise 
intolerance and postural giddiness. Signs include an impaired Heart rate 
variability (HRV), resting tachycardia, nocturnal hypertension and orthostatic 
hypotension. 
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Impaired HRV     
 Beat to beat variation in heart rate and heart rate changes with respect to 
respiration is a function of both parasympathetic and sympathetic activity. In 
normal subjects there is high degree of beat to beat heart rate variability and this 
HRV increases with inspiration and decreases with expiration. A decreased 
HRV is seen very early in the course of development of CAN. 
Resting tachycardia 
Sympathetic over activity along with a parasympathetic denervation produces a 
resting tachycardia with rates > 100 /mt. A complete cardiac denervation is 
indicated by a fixed heart rate not responding stress, exercise or sleep. 
Exercise intolerance 
Decreased heart rate, blood pressure and cardiac output response to exercise 
occur due to CAN in diabetics. 
Abnormal Blood Pressure regulation 
 Normally a dominant vagus output and decrease in adrenrgic output at 
night produces a reduced blood pressure at night. An altered pattern with 
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parasympathetic denervation and sympathetic over activity in CAN produces 
nocturnal hypertension in diabetic patients. 
Orthostatic hypotension 
As the diasease progresses there is sympathetic denervation in diabetic patients 
resulting in impaired vasoconstriction of peripheral vascular beds which results 
in orthostatic hypotension. 
DIASTOLIC DYSFUNCTION : 
 Two dimensional echo cardiographic evaluation of diastolic dysfunction  
was done in all subjects both cases and control. Echocardiography was done 
using harmonic imaging by standard protocol. In the apical 4 chamber view 
Transmitral inflow velocities was obtained using pulsed wave dopppler. All 
measurements were averaged over three consecutive cardiac cycles. 
Echocardiographer was unaware of the research to prevent any observer bias in 
interpretation. Following measurements were done 
1) E-wave –Transmitral-early rapid filling velocity in diastole 
2) A-wave –late filling velocity- atrial contraction wave 
3) E/A ratio 
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4) IVRT-Isovolumetric relaxation time  
5) DT-Deceleration time 
6) E/e’ ratio 
 Diastolic dysfunction was defined to be present if any of the following finding 
was observed 
1) E/A ratio <1 or >2 
2) DT < 150 msec or > 220 milliseconds 
3) IVRT < 60 ms or > 100 milliseconds 
4) E/e’ ratio >15 
The diastolic dysfunction can be graded by the following grade 
   
 Grade 1 (mild dysfunction): impaired relaxation with normal filling 
pressure 
    Grade 2 (moderate dysfunction): pseudonormalized mitral inflow pattern 
   
 Grade 3 (severe reversible dysfunction): reversible restrictive (high filling 
pressure) 
   
 Grade 4 (severe irreversible dysfunction): irreversible restrictive (high 
filling pressure) 
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FIGURE 2: MITRAL INFLOW RATIOS , TISSUE DOPPLER IMAGING RATIOS, DECELERATION TIME IN 
VARIOUS DEGREES OF DIASTOLIC DYSFUNCTION 
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DISTRIBUTION OF CASE AND CONTROL GROUP 
Among the 50 patients in the case group 30 were male and 20 female. In the 
control arm among 50 patients 29 were male and 21 female were present. 
 
TABLE 1: 
 
 
DIASTOLIC DYSFUNCTION IN CASE AND CONTROL 
TABLE 2: 
 
 
 
 
0 
10 
20 
30 
40 
50 
60 
CASE CONTROL 
NO: OF FEMALE 
NO: OF MALE 
SEX CASES CONTROL 
MALE 30 29 
FEMALE 20 21 
PARAMETER CASES CONTROL 
DIASTOLIC DYSFUNCTION 30 7 
NO DIASTOLIC DYSFUNCTION 20 43 
PERCENTAGE 60% 14% 
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DISTRIBUTION OF DIASTOLIC DYSFUNCTION IN CASE AND CONTROL GROUP 
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CONTROL 
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30 
40 
50 
PRESENCE OF DIASTOLIC 
DYSFUNCTION ABSENCE OF DIASTOLIC 
DYSFUNCTION 
CASES 
CONTROL 
DIASTOLIC DYSFUNCTION 
AMONG CASES 
DIASTOLIC 
DYSFUNCTION 
NO DIASTOLIC 
DYSFUNCTION 
60% 
40% 
DIASTOLIC DYSFUNCTION 
AMONG CONTROL 
DIASTOLIC 
DYSFUNCTION 
NO DIASTOLIC 
DYSFUNCTION 
86% 
14% 
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RELATIONSHIP OF DIASTOLIC DYSFUNCTION WITH AGE OF PATIENTS 
The study population was categorized as age < 45 yrs and > 45 yrs and tabulated 
as follows 
 
TABLE 3: 
PARAMETER AGE < 45 YRS AGE > 45 YRS TOTAL 
DIASTOLIC DYSFUNCTION 7 23 30 
NO DIASTOLIC DYSFUNCTION 6 14 20 
TOTAL 13 37 50 
PERCENTAGE WITH 
DIASTOLIC DYSFUNCTION 
53.8% 62.16% 60% 
 
 
0 
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40 
AGE < 45 YRS AGE > 45 YRS 
CASES BASED ON AGE 
CASES BASED ON 
AGE 
AGE < 45 YRS AND DIASTOLIC 
DYSFUNCTION 
DIASTOLIC 
DYSFUCNTION 
NO DIASTOLIC 
DYSFUCNTION 
53.8% 
46.2% 
AGE > 45 YRS AND DIASTOLIC 
DYSFUNCTION 
DIASTOLIC 
DYSFUCNTION 
NO DIASTOLIC 
DYSFUCNTION 
46.2% 
62.2% 
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RELATIONSHIP OF DIASTOLIC DYSFUNCTION WITH HBA1C LEVELS OF 
PATIENTS 
TABLE 4: 
PARAMETER HBA1C <7.5gm% HBA1C > 7.5 gm% TOTAL 
DIASTOLIC DYSFUNCTION 14 16 30 
NO DIASTOLIC DYSFUNCTION 17 3 20 
TOTAL 31 19 50 
PERCENTAGE WITH 
DIASTOLIC DYSFUNCTION 
45.2% 84.2% 60% 
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DYSFUNCTION 
DIASTOLIC 
DYSFUNCTION 
NO DIASTOLIC 
DYSFUNCTION 
84.2% 
15.8% 
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DURATION OF DIABETES AND DIASTOLIC DYSFUNCTION 
 
TABLE 5: 
PARAMETER DURATION 6-10 YRS DURATION 11-15 
YRS 
TOTAL 
DIASTOLIC DYSFUNCTION 22 8 30 
NO DIASTOLIC DYSFUNCTION 16 4 20 
TOTAL 38 12 50 
PERCENTAGE WITH 
DIASTOLIC DYSFUNCTION 
57.9% 66.7% 60% 
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RETINOPATHY AND DIASTOLIC DYSFUNCTION 
In the study all 100 subjects were examined clinically for the presenc of diabetic 
retinopathy with fundus examination after using mydriatics. They were tabulated 
as either presence of nonproliferative diabetic retinopathy (NPDR), proliferative 
diabetic retinopathy (PDR) and no diabetic retinopathy. The results were 
tabulated 
 
DURATION 6-10 YRS AND 
DIASTOLIC DYSFUNCTION 
DIASTOLIC 
DYSFUNCTIO
N 
NO DIASTOLIC 
DYSFUNCTIO
N 
57.942.1
DURATION 11-15 YRS AND 
DIASTOLIC DYSFUNCTION 
DIASTOLIC 
DYSFUNCTION 
NO DIASTOLIC 
DYSFUNCTION 
66.7
33.3% 
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TABLE 6: 
PARAMETER RETINOPATHY NO RETINOPATHY TOTAL 
DIASTOLIC DYSFUNCTION 9 21 30 
NO DIASTOLIC DYSFUNCTION 3 17 20 
TOTAL 12 38 50 
PERCENTAGE WITH 
DIASTOLIC DYSFUNCTION 
75% 55.26% 60% 
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RETINOPATHY NO RETINOPATHY 
CASES BASED ON PRESENCE OF RETINOPATHY 
CASES BASED ON PRESENCE OF 
RETINOPATHY 
RETINOPATHY AND DIASTOLIC DYSFUNCTION 
DIASTOLIC DYSFUNCTION 
NO DIASTOLIC DYSFUNCTION 75% 
25% 
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AUTONOMIC NEUROPATHY AND DIASTOLIC DYSFUNCTION 
In the study presence of cardiac autonomic neuropathy was defined when patient 
had orthostatic hypotension, which was defined as the fall in Systolic BP > 
30mm of Hg or a Diastolic BP fall of more than 10 mm hg on standing for more 
than 3 minutes. For this the systolic and diastolic blood pressure was measured 
in all patients while sitting, immediately on standing and 3 minutes after 
standing. A sustained fall in SBP/DBP after 3 minutes is taken as positive and 
petients were computed as having autonomic neuropathy and not having 
autonomic neuropathy 
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TABLE 7: 
PARAMETER AUTONOMIC 
NEUROPATHY 
NO AUTONOMIC 
NEUROPATHY 
TOTAL 
DIASTOLIC DYSFUNCTION 9 21 30 
NO DIASTOLIC DYSFUNCTION 3 17 20 
TOTAL 12 38 50 
PERCENTAGE WITH 
DIASTOLIC DYSFUNCTION 
75% 55.26% 60% 
 
 
STATISTICAL ANALYSIS: 
 All the variables and their data were analysed for percentage, mean, 
standard deviation,‘t’ test and chi square test. Those variables which were not 
distributed in normal distribution were transformed for the analysis. The ‘t’-test 
was used to study the quantitative data while chi square test was used to study 
the qualitative data. A ‘P’ value of <0.05 is considered as statistically 
significant. 
 
AUTONOMIC NEUROPATHY AND 
DIASTOLIC DYSFUNCTION 
DIASTOLIC DYSFUNCTION 
NO DIASTOLIC 
DYSFUNCTION 
75% 
25% 
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TABLE 8: MEAN AND SANDARD DEVIATION OF THE VARIABLES UNDER STUDY 
Sl 
no 
VARIABLES CASE 
MALE 
(MEAN+/-SD) 
CASE 
FEMALE 
(MEAN+/-SD) 
CONTROL 
MALE 
(MEAN+/-SD) 
CONTROL 
FEMALE 
(MEAN+/-SD) 
1. AGE IN YEARS 52+/-12 48+/-11 51+/-9 50+/-9 
2. DURATION OF DIABETES 
IN YEARS 
12+/-5 11+/-3 - - 
3. BODY MASS 
INDEX(KG/M2) 
27.4+/-2 26.2+/-2.4 23+/-1.5 24+/-1.2 
4. WAIST HIP RATIO 0.95+/-0.15 0.83+/-0.17 0.75+/-0.17 0.75+/-0.14 
5. TOTAL CHOLESTROL 221+/-24 231+/-23 140+/-12 145+/-13 
6. TRIGLYCERIDES 206+/-26.7 197+/-25.4 130+/-10 128+/-12 
7. LDL –CHOLESTROL 145+/-17.8 149+/-13 95+/-13 103+/-9 
8. HDL-CHOLESTROL 40+/-7 38+/-6 45+/-3 44+/-2 
 
Sl 
no 
 
VARIABLES 
 
CASE 
MALE 
(MEAN+/-SD) 
 
CASE 
FEMALE 
(MEAN+/-SD) 
 
CONTROL 
MALE 
(MEAN+/-SD) 
 
CONTROL 
FEMALE 
(MEAN+/-SD) 
9. BLOOD SUGAR LEVEL 136+/-20.1 134+/-19 90+/-6 85+/-8 
10. HBA1C % 8.2+/-2.80 8.1+/-1.5 - - 
11. E/A RATIO 0.80+/-0.12 0.79+/-0.13 1.20+/-0.2 1.18+/-0.10 
12. IVRT(ms) 80+/-12 81+/-9 94+/-15 96+/-12 
13. DT(ms) 175+/-21 179+/-18 160+/-24 153+/-25 
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14. EJECTION FRACTION% 55+/-3 54+/-2 59+/-5 58+/-3 
15. DIASTOLIC DYSFUNCTION 19(63.33%) 11(55%) 4(13.79%) 3(14.2%) 
 
INDEX 
HBA1C-GLYCATED HEMOGLOBIN; 
LDL-LOW DENSITY LIPOPROTEIN;  
HDL- HIGH DENSITY LIPOPROTEIN 
E-EARLY DIASTOLIC VELOCITY (CM/S) 
A-ATRIAL WAVE (CM/S) 
IVRT-ISOVOLUMETRIC RELAXATION TIME 
DT-DECELERATION TIME 
TABLE 9: RELATIONSHIP OF DIASTOLIC DYSFUNCTION WITH THE DEPENDENT VARIABLES 
AND CORRESPONDING ‘P’ VALUES 
SL 
NO 
VARIABLES DD PRESENT DD ABSENT TOTAL % ‘P’ 
VALUE 
1. AGE <45 YEARS(n=13) 7(53.8%) 6 23% <0.05 
2. AGE>45 YEARS(n=37) 23(62.16%) 14 76.6% <0.02 
3. HBA1C<7.5% 14(45.16%) 17 46.67% <0.05 
4. HBA1C>7.5% 16(84.21) 3 53.3% <0.02 
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5. DURATION OF DIABETES 6-10 YRS 22(57.89%) 16 73.33% <0.02 
6. DURATION OF DIABETES 11-
16YRS 
8(66.66%) 4 26.66% <0.05 
7. RETINOPATHY PRESENT 9(75%) 3 30% <0.02 
8. AUTONOMIC NEUROPATHY 
PRESENT 
9(75%) 3 30% <0.02 
DD- DIASTOLIC DYSFUNCTION 
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DISCUSSION 
 
 
 
91 
 
Table 1 shows that there were total of 50 patients in cases under study and total 
of 50 matched controls. Of the cases 30 were male and 20 were female. Of the 
control group 29 were male and 21 were female. 
Table 2 shows that  
i) Of the total 50 patients in the cases arm 30 had diastolic dysfunction 
which is 60% prevalence.  
ii) On the control arm a total of 7 had diastolic dysfunction which equals 
to 14%.  
Table 3 shows that  
i) A total of 13 patients were of age <45 years of which 7 had diastolic 
dysfunction. This equals 53.8% prevalence.  
ii) The remaining 37 patients were in the age group >45 years. A total of 
23 patients in this category had diastolic dysfunction which equals 
62.16%. 
Table 4 shows that  
i) 31 patients in cases arm had HBA1c less than 7.5 gm% and 19 had 
HBA1c greater than7.5gm%.  
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ii) 14 patients with HBA1c less than 7.5 gm% had diastolic dysfunction 
with a prevalence of 45.2%. 
iii)  16 patients with HBA1c greater than 7.5 gm% had diastolic 
dysfunction with an prevalence of 84.2%. 
Table 5 shows that  
i) 38 patients had diabetes mellitus for 6-10 years and 12 had duration 
between11-15 years.  
ii) 22 patients with duration 6-10 years had diastolic dysfunction with an 
prevalence of 57.9%.  
iii) 8 patients with duration of diabetes 11-15 years had diastolic 
dysfunction with an prevalence of 66.67% 
Table 6 shows that a total of 12 patients had diabetic retinopathy while the 
remaining 38 did not show features of diabetic retinopathy. Of the 12 patients 9 
had diastolic dysfunction with a prevalence of 75%. 
Table 7 shows that a total of 12 patients had autonomic dysfunction and 
remaining 38 patients did not have autonomic dysfunction. Of the 12 patients 
with autonomic dysfunction 9 had diastolic dysfunction with an incidence of 
75%. 
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Table 8 shows that  
i) The mean body mass index, waist hip ratio, total cholesterol, LDL 
cholesterol, in cases was high when compared to controls. 
ii)  The mean HDL cholesterol was lower in cases than in the control 
group.  
iii) The mean E/A ratio was lower in the cases that in the control group.  
iv) 19 males in cases arm had diastolic dysfunction with an incidence of 
63.3%. 11 females in cases arm had diastolic dysfunction with an 
incidence of 55%. This was statistically significant with a ‘p’-value of 
<0.02. 
v) 4 males and 3 females in the control arm had diastolic dysfunction 
with an incidence of 13.79% and 14.2%. 
Table 9 shows that  
i) The incidence of diastolic dysfunction is more in age >45 years with 
the Statistical ‘p’ value of <0.02. 
ii) The incidence of diastolic dysfunction is more in the HBA1c > 7.5 
gm% with a statistical ‘p’ value of <0.02 
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iii) The incidence of diastolic dysfunction occurs more often after a 5 
years duration with an incidence in 6-10 years of 73.33% of total and a 
stastical ‘p’ value of <0.02. 
iv) The incidence of diastolic dysfunction 75 % when the patient develops 
diabetic retinopathy. 
v) The incidence of diastolic dysfunction 75 % when the patient develops 
diabetic autonomic neuropathy. 
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CONCLUSION 
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 Diabetes Mellitus causes serious morbidities one of which is 
cardiovascular. The occurrence of coronary artery disease and systolic 
dysfunction are well known. However the prevalence of a diastolic 
dysfunction even in asymptomatic patients independent of a CAD is a relatively 
new observation. It is also obvious that, diastolic dysfunction correlates well 
with diabetes duration, micro vascular abnormalities obesity index, lipid 
profile and HbA1c. Diastolic dysfunction, being a marker of Diabetic 
Cardiomyopathy, may be useful as the predictor of heart failure with 
preserved ejection fraction and mortality in the medium to long term. At 
present the treatment options for a diastolic heart failure with normal systolic 
function are very limited. It is prudent to screen for diastolic dysfunction 
through the markers of insulin resistance for an early identification and 
treatment of the determinants so as to prevent the progression to full blown 
heart failure. All these determinants and diabetes in itself stem from the 
common patho-physiology of insulin resistance. Recently trials have shown a 
cardio-protective effect for metformin, probably because it increases insulin 
sensitivity. Studies are needed further to crystallize our knowledge, to 
understand the pathophysiology of Diabetic cardiomyopathy which at present 
looks very complex and also to ensure better management so as to reduce the 
morbidity and mortality associated with Diastolic Dysfunction. 
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ANNEXURE 1 
A Study of Diastolic dysfunction in asymptomatic type 2 diabetes 
mellitus with normal systolic function 
PROFORMA 
 
Name of the patient  : 
 
AGE/SEX    : 
 
OP NO.   : 
 
Complaints : 
 
Date     : 
 
History of Presenting illness: 
 
 
 
 
Past history  
 
Duration of Diabetes     : 
 
H/O Systemic hypertension    : 
 
H/O Coronary Artery Heart Disease   :  
 
104 
 
H/O Valvular Heart disease    : 
 
Personal history: 
On General examination 
 
 
 
 
 
Anthropometric examination 
Height:   
 
Weight :     
 
BMI 
 
High waist circumference 
 
Waist Hip Ratio(WHR) 
 
Vitals 
 
CVS : 
 
RS : 
 
P/A : 
  
CNS : 
 
 
105 
 
FUNDUS EXAMINATION: 
 
 
Investigations  
 
Fasting Blood sugar(mg%)    : 
 
Postprandial blood sugar(mg%)  : 
 
Lipid profile     : 
 
Total cholesterol    : 
 
Triglycerides     : 
 
LDL      : 
 
HDL      : 
 
Electrocardiogram    : 
 
Echocardiography    : 
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ANNEXURE 2 
MASTER CHART FOR CASES 
 
 
SL 
no 
Name Age/ 
Sex 
Diab 
etes-Dura 
tion(YRS
)  
H/O 
CAD/ 
SHT/ 
VHD 
FBS 
(MG%) 
HB 
A1C 
BMI 
Kg/m2 
WHR FUN 
DUS 
AUTO 
NOMIC 
NEURO 
PATHY 
TC 
TGL 
LDL 
HDL 
(MG%) 
ECG ECHO 
E/A 
IVRT 
DT 
E/e’ 
1. Arivoli 52/ M 7 Nil 156 8 % 22.9 0.8 NO-DR NO TC-180 
TGL-130 
LDL-110 
HDL-45 
Wnl E/A-0.6 
IVRT-124msec 
DT-240 msec 
 
2. Abdullah  53/ 
M 
6 Nil 148 8.2% 23.5 0.8 NO-DR NO TC-190 
TGL-133 
LDL-135 
HDL-40 
Wnl E/A-0.8 
IVRT-106msec 
DT-225 msec 
 
3. Alagammal  51/ 
F 
8 Nil 135 7.2% 26.1 1.3 NO-DR NO TC-240 
TGL-180 
LDL-160 
HDL-34 
Wnl E/A-0.5 
IVRT-140msec 
DT-250 msec 
 
4. Bharath  56/ 
M 
9 Nil 170 7.1% 22.3 0.8 NO-DR NO TC-185 
TGL-146 
LDL-140 
HDL-39 
Wnl E/A-0.7 
IVRT-114msec 
DT-230 msec 
 
 
5. Bhagyalakshmi  49/ 
F 
6 Nil 160 6.5% 25.6 1.2 BDR YES TC-225 
TGL-202 
LDL-175 
HDL-36 
Wnl E/A-0.9 
IVRT-104msec 
DT-223 msec 
 
6. Bharani 62/ 
M 
12 Nil 143 8.5% 23 0.8 BDR YES TC-198 
TGL-157 
LDL-139 
HDL-38 
Wnl E/A-1.5 
IVRT-80msec 
DT-210 msec 
E/e’-18 
7. Buvaneswari  48/ 
F 
6 Nil 129 6.9% 22 0.7 NO-DR NO TC-180 
TGL-150 
LDL137 
HDL-40 
Wnl E/A-0.6 
IVRT-124msec 
DT-240 msec 
 
8. Bruntha 64/ 
M 
13 Nil 162 8% 25.5 1.1 BDR YES TC-222 
TGL-180 
LDL-150 
HDL-30 
Wnl E/A-1.6 
IVRT-80msec 
DT-210 msec 
E/e’-17 
9. Chellamal  50/ 
F 
7 Nil 134 7.2% 23 0.9 NO-DR NO TC-170 
TGL-140 
LDL-150 
HDL-36 
Wnl E/A-0.7 
IVRT-114msec 
DT-230 msec 
 
10. Chellaiah  64/ 
M 
13 Nil 156 8.5% 27.2 1.4 BDR YES TC-250 
TGL-190 
LDL-176 
HDL-32 
Wnl E/A-1.8 
IVRT-80msec 
DT-210 msec 
E/e’-19 
11. Durai  56/ 
M 
6 Nil 176 8.2% 27.3 1.7 NO-DR NO TC-198 
TGL-145 
LDL-120 
HDL-40 
Wnl E/A-0.8 
IVRT-106msec 
DT-225 msec 
 
12. David  58/ 
M 
15 Nil 134 8% 28 1.6 BDR YES TC-270 
TGL-180 
LDL-150 
HDL-30 
Wnl E/A-1.6 
IVRT-80msec 
DT-210 msec 
E/e’-18 
13. Dinakar  42/ 
M 
6 Nil 156 8.3% 22 0.8 B-DR YES TC-197 
TGL-130 
LDL-143 
HDL-40 
Wnl E/A-0.9 
IVRT-104msec 
DT-223 msec 
 
14. Dinesh  54/ 
M 
8 Nil 140 7.2% 21 0.7 NO-DR NO TC-240 
TGL-190 
LDL-170 
HDL-32 
Wnl E/A-0.6 
IVRT-124msec 
DT-240 msec 
 
15. Dhanam  60/ 
F 
14 Nil 179 8.4% 26 1.2 BDR YES TC-247 
TGL-180 
LDL-140 
HDL-30 
Wnl E/A-1.9 
IVRT-80msec 
DT-210 msec 
E/e’-20 
16. Ibrahim  45/ 
M 
6 Nil 180 6.5% 23 0.8 NO-DR NO TC-235 
TGL-232 
LDL-195 
HDL-34 
Wnl E/A-0.9 
IVRT-104msec 
DT-223 msec 
 
17. Elumalai  50/ 
M 
9 Nil 128 7% 22 0.8 NO-DR NO TC-190 
TGL-150 
LDL-145 
HDL-34 
Wnl E/A-0.7 
IVRT-114msec 
DT-230 msec 
 
18. Elavarasi  43/ 7 Nil 138 7.4% 23.1 0.9 NO-DR NO TC-170 Wnl E/A-0.8 
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F TGL-130 
LDL119 
HDL-41 
IVRT-106msec 
DT-225 msec 
 
19. Ganesan  56/ 
M 
8 Nil 129 7.6% 23 0.8 NO-DR NO TC-190 
TGL-130 
LDL-140 
HDL-38 
Wnl E/A-0.5 
IVRT-140msec 
DT-250 msec 
 
20. Ganthimathi  39/ 
F 
6 Nil 137 7.1% 24.4 1.1 BDR YES TC-230 
TGL-160 
LDL-136 
HDL-36 
Wnl E/A-0.8 
IVRT-106msec 
DT-225 msec 
 
21. Gunaselan  63/ 
M 
12 Nil 143 6.5% 25.5 1 N0-DR NO TC-250 
TGL-165 
LDL-140 
HDL-34 
Wnl E/A-1.7 
IVRT-80msec 
DT-210 msec 
E/e’-19 
22. Gayathri  45/ 
F 
7 Nil 167 7.7% 23.2 1 NO-DR NO TC-220 
TGL-140 
LDL-120 
HDL-30 
Wnl E/A-0.6 
IVRT-124msec 
DT-240 msec 
 
23. Kavitha  40/ 
F 
7 Nil 149 7.3% 22.2 0.7 NO-DR NO TC-198 
TGL-130 
LDL-146 
HDL-37 
Wnl E/A-0.8 
IVRT-106msec 
DT-225 msec 
 
24. Kathiravan  45/ 
M 
8 Nil 152 8% 28 1.7 NO-DR NO TC-210 
TGL-170 
LDL-150 
HDL-32 
Wnl E/A-0.8 
IVRT-106msec 
DT-225 msec 
 
25. Kumar  55/ 
M 
8 Nil 170 6.7% 25.1 1.1 NO-DR NO TC-238 
TGL-165 
LDL-145 
HDL-35 
Wnl E/A-0.7 
IVRT-114msec 
DT-230 msec 
 
26. Krishnan  60/ 
M 
10 Nil 175 7.6% 27.3 1.6 NO-DR NO TC-225 
TGL-152 
LDL-165 
HDL-36 
Wnl E/A-0.5 
IVRT-140msec 
DT-250 msec 
 
27. Krishnaveni  62/ 
F 
7 Nil 141 7.8% 21 0.7 BDR YES TC-197 
TGL-160 
LDL-155 
HDL-37 
Wnl E/A-0.6 
IVRT-124msec 
DT-240 msec 
 
28. Krishnakumar 43/ 
M 
7 Nil 156 6.4% 22.2 0.8 NO-DR NO TC-176 
TGL-120 
LDL 100 
HDL-39 
Wnl E/A-0.5 
IVRT-140msec 
DT-250 msec 
 
29. Lalitha  42/ 
F 
8 Nil 159 7.9% 22.6 0.7 NO-DR NO TC-180 
TGL-130 
LDL-120 
HDL-35 
Wnl E/A-0.9 
IVRT-104msec 
DT-223 msec 
 
30. Logesh 37/ 
M 
6 Nil 176 8% 27.9 1.7 NO-DR NO TC-210 
TGL-170 
LDL-146 
HDL-36 
Wnl E/A-0.7 
IVRT-114msec 
DT-230 msec 
 
31. Loorth mary 48/ 
F 
6 Nil 157 7.9% 21 0.7 NO-DR NO TC-235 
TGL-155 
LDL-130 
HDL-37 
Wnl Normal 
disastolic 
function 
32. Mohammed  56/ 
M 
7 Nil 139 7.6% 22.2 0.8 NO-DR NO TC-210 
TGL-156 
LDL-110 
HDL-36 
Wnl Normal 
diastolic 
function 
33. Manikam  59/ 
M 
6 Nil 130 7.4% 22.5 0.7 NO-DR NO TC-178 
TGL-110 
LDL-125 
HDL-32 
Wnl Normal 
diastolic 
function 
34. Moorthy  57/ 
M 
9 Nil 164 7.3% 23.1 0.7 BDR YES TC-210 
TGL-140 
LDL-120 
HDL-35 
Wnl Normal 
diastolic 
function 
35. Mary  62/ 
M 
8 Nil 174 6.8% 21.6 0.7 NO-DR NO TC-180 
TGL-134 
LDL-145 
HDL-40 
Wnl Normal 
diastolic 
function 
36. Naseer  43/ 
M 
7 Nil 178 6.6% 23.3 0.8 NO-DR NO TC-240 
TGL-180 
LDL-160 
HDL-34 
Wnl Normal 
diastolic 
function 
37. Navin  56/ 
M 
12 Nil 157 6.4% 21.7 0.7 NO-DR NO TC-185 
TGL-146 
LDL-140 
HDL-39 
Wnl Normal 
diastolic 
function 
38. Petchiammal  43/ 
F 
6 Nil 159 6.9% 26.1 1.5 NO-DR NO TC-215 
TGL-192 
LDL-165 
HDL-36 
Wnl Normal 
diastolic 
function 
39. Perumalamal  54/ 
F 
10 Nil 145 7.1% 22 0.7 BDR YES TC-178 
TGL-147 
Wnl Normal 
diastolic 
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LDL-120 
HDL-34 
function 
40 Perumal  54/ 
M 
9 Nil 149 7.3% 27.1 1.6 NO-DR NO TC-175 
TGL-120 
LDL 
138 
HDL-34 
Wnl Normal 
diastolic 
function 
41. Peratchi  55/ 
F 
11 Nil 139 7.9% 23.9 1.1 NO-DR NO TC-176 
TGL-120 
LDL-130 
HDL-35 
Wnl Normal 
diastolic 
function 
42. Pushpam  56/ 
F 
12 Nil 140 7% 22 0.7 NO-DR NO TC-196 
TGL-146 
LDL-125 
HDL-30 
Wnl Normal 
diastolic 
function 
43. Kathar Moideen  42/ 
 
7 Nil 147 6.5% 27.9 1.7 NO-DR NO TC-220 
TGL-170 
LDL-140 
HDL-34 
Wnl Normal 
diastolic 
function 
44. Rathinam  55/M 
 
12 Nil 147 7.3% 26 1.2 NO-DR NO TC-185 
TGL-146 
LDL-140 
HDL-39 
Wnl Normal 
diastolic 
function 
45. Revathy  49/F 
 
6 Nil 143 6.4% 26.3 1.6 NO-DR NO TC-225 
TGL-202 
LDL-175 
HDL-36 
Wnl Normal 
diastolic 
function 
46. Rasathi  60/F 
 
13 Nil 168 6.3% 22.7 0.7 NO-DR NO TC-178 
TGL-150 
LDL-139 
HDL-38 
Wnl Normal 
diastolic 
function 
47. Sheik  57/M 
 
7 Nil 156 6.6% 22.6 0.7 NO-DR NO TC-180 
TGL-130 
LDL134 
HDL-35 
Wnl Normal 
diastolic 
function 
48. Sathik  52/ 
M 
8 Nil 154 6.1% 21.9 0.7 BDR YES TC-180 
TGL-130 
LDL-110 
HDL-45 
Wnl Normal 
diastolic 
function 
49. Salim  56/M 
 
10 Nil 165 7.2% 27.3 1.6 NO-DR NO TC-190 
TGL-133 
LDL-135 
HDL-40 
Wnl Normal 
diastolic 
function 
50 Selvi  50/M 
 
6 Nil 187 7.7% 21.1 0.7 NO-DR NO TC-240 
TGL-180 
LDL-160 
HDL-34 
Wnl Normal 
diastolic 
function 
MASTER CHART FOR CONTROL 
Sl no  Name  Age/ 
Sex 
Diabe 
Tes 
Dura 
Tion 
Cad/ 
sht 
Fbs 
Mg% 
Hb 
a1c 
BMI WHR FUN 
DUS 
AUTO 
NOMIC 
NEURO 
PATHY 
LIPID 
PROFI 
LE 
ECG ECHO 
1. SHUNMUGAM 45M Nil Nil 92 6.4 22.9 0.8 NAD Nil TC-180 
TGL-130 
LDL-110 
HDL-45 
Wnl Normal 
diastolic 
function 
2. MAYANDI 55M Nil Nil 95 6.3 23.5 0.8 NAD Nil TC-190 
TGL-133 
LDL-135 
HDL-40 
Wnl Normal 
diastolic 
function 
3. MASANAM 57M Nil  Nil  86 5.6 23.1 0.8 NAD Nil  TC-170 
TGL-120 
LDL-140 
HDL-39 
Wnl E/A-0.5 
IVRT-140msec 
DT-250 msec 
4. PARAMSIVAM 52M Nil Nil 90 5.7 22.3 0.8 NAD Nil TC-185 
TGL-146 
LDL-140 
HDL-40 
Wnl Normal 
diastolic 
function 
5. MOHAMED 61M Nil Nil 79 5.4 24.6 1.0 NAD Nil TC-185 
TGL-140 
LDL-135 
HDL-36 
Wnl Normal 
diastolic 
function 
6. JEBAKANI 47F Nil  Nil  88 6.1 23 0.8 NAD Nil  TC-198 
TGL-145 
LDL-130 
HDL-38 
Wnl Normal 
diastolic 
function 
7. MURUGAN 52M Nil Nil 94 6.3 22 0.7 NAD Nil TC-180 
TGL-150 
Wnl Normal 
diastolic 
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LDL137 
HDL-40 
function 
8. SHAKILA 58F Nil Nil 99 6.2 23 0.8 NAD Nil TC-165 
TGL-132 
LDL-115 
HDL-40 
Wnl Normal 
diastolic 
function 
9. RAJESWARI 63F Nil  Nil  87 5.9 22 0.8 NAD Nil  TC-190 
TGL-150 
LDL-125 
HDL-34 
Wnl Normal 
diastolic 
function 
10. SOURIAMMAL 45F Nil Nil 85 6.0 23.1 0.8 NAD Nil TC-170 
TGL-130 
LDL120 
HDL-42 
Wnl Normal 
diastolic 
function 
11. DURAI 43M Nil Nil 93 6.4 23 0.8 NAD Nil TC-190 
TGL-130 
LDL-110 
HDL-38 
Wnl Normal 
diastolic 
function 
12. GURUSAMY 59M Nil  Nil  97 6.3 24.4 0.9 NAD Nil  TC-160 
TGL-100 
LDL-106 
HDL-47 
Wnl Normal 
diastolic 
function 
13. MARIA THERASA 60F Nil Nil 94 5.6 25.5 1.0 NAD Nil TC-250 
TGL-165 
LDL-140 
HDL-34 
Wnl Normal 
diastolic 
function 
14. KARUPASAMY 65M Nil Nil 91 5.7 23.2 0.8 NAD Nil TC-205 
TGL-140 
LDL-120 
HDL-35 
Wnl Normal 
diastolic 
function 
15. FATHIMA BEEVI 59F Nil  Nil  86 5.4 22.2 0.7 NAD Nil  TC-198 
TGL-130 
LDL-146 
HDL-38 
Wnl E/A-0.8 
IVRT-106msec 
DT-225 msec 
 
16. SARASWATHY 51F Nil Nil 90 6.1 25 1.1 NAD Nil TC-210 
TGL-170 
LDL-150 
HDL-32 
Wnl Normal 
diastolic 
function 
17. SARAVANAN 46M Nil Nil 79 6.3 24.1 1.0 NAD Nil TC-238 
TGL-165 
LDL-145 
HDL-35 
Wnl Normal 
diastolic 
function 
18. GANESAN 40M Nil  Nil  88 6.2 27.3 1.2 NAD Nil  TC-235 
TGL-152 
LDL-150 
HDL-36 
Wnl Normal 
diastolic 
function 
19. AMBIGAI 54F Nil Nil 94 5.9 21 0.7 NAD Nil TC-197 
TGL-160 
LDL-155 
HDL-37 
Wnl Normal 
diastolic 
function 
20. RAHMATH KHAN 49M Nil Nil 99 6.0 22.2 0.8 NAD Nil TC-156 
TGL-110 
LDL 90 
HDL-39 
Wnl Normal 
diastolic 
function 
21. SUNDARAM 65M Nil  Nil  87 5.4 22.6 0.8 NAD Nil  TC-180 
TGL-130 
LDL-120 
HDL-40 
Wnl Normal 
diastolic 
function 
22. ABDUL KATHER 67M Nil Nil 85 6.1 26.9 1.2 NAD Nil TC-250 
TGL-170 
LDL-166 
HDL-36 
Wnl Normal 
diastolic 
function 
23. PETER 56M Nil Nil 93 6.3 21 0.8 NAD Nil TC-170 
TGL-155 
LDL-130 
HDL-37 
Wnl E/A-0.9 
IVRT-104msec 
DT-223 msec 
24. SUDALAI 59M Nil  Nil  94 6.2 22.2 0.8 NAD Nil  TC-178 
TGL-147 
LDL-120 
HDL-34 
Wnl Normal 
diastolic 
function 
25. PONNI 43F Nil Nil 91 5.9 22.5 0.8 NAD Nil TC-175 
TGL-120 
LDL 
138 
HDL-34 
Wnl Normal 
diastolic 
function 
26. LAXSHMANAN 47M Nil Nil 86 6.0 23.1 0.9 NAD Nil TC-176 
TGL-120 
LDL-130 
HDL-35 
Wnl Normal 
diastolic 
function 
27. ESAKIAMMAL 61F Nil  Nil  90 6.4 21.6 0.7 NAD Nil  TC-196 Wnl Normal 
110 
 
TGL-146 
LDL-125 
HDL-30 
diastolic 
function 
28. LATHA 46F Nil Nil 79 6.3 23.3 0.8 NAD Nil TC-220 
TGL-170 
LDL-140 
HDL-34 
Wnl E/A-0.8 
IVRT-106msec 
DT-225 msec 
29. RAMESH 57M Nil Nil 88 6.0 21.7 0.7 NAD Nil TC-185 
TGL-146 
LDL-140 
HDL-39 
Wnl Normal 
diastolic 
function 
30. PARAMESWARI 49F Nil  Nil  94 6.4 26.1 1.1 NAD Nil  TC-225 
TGL-202 
LDL-175 
HDL-36 
Wnl Normal 
diastolic 
function 
31. MUNIAMMAL 59F Nil Nil 97 6.3 22 0.7 NAD Nil TC-178 
TGL-150 
LDL-139 
HDL-38 
Wnl Normal 
diastolic 
function 
32. PALANIAPPAN 44M Nil Nil 88 5.6 27.1 1.2 NAD Nil TC-180 
TGL-130 
LDL134 
HDL-35 
Wnl Normal 
diastolic 
function 
33. JENIFER 41F Nil  Nil  94 5.7 23.9 0.9 NAD Nil  TC-180 
TGL-130 
LDL-110 
HDL-45 
Wnl Normal 
diastolic 
function 
34. POOLPANDI 54M Nil Nil 99 5.4 22 0.8 NAD Nil TC-170 
TGL-130 
LDL-115 
HDL-40 
Wnl E/A-0.8 
IVRT-106msec 
DT-225 msec 
35. MUTHIAH 56M Nil Nil 87 6.1 26.9 1.2 NAD Nil TC-240 
TGL-180 
LDL-160 
HDL-34 
Wnl Normal 
diastolic 
function 
36. ANTHONIAMMAL  63F Nil  Nil  85 6.3 26 1.1 NAD Nil  TC-220 
TGL-170 
LDL-150 
HDL-30 
Wnl Normal 
diastolic 
function 
37. BALASUBRAMANIAN 60M Nil Nil 93 6.2 25.3 1.1 NAD Nil TC-220 
TGL-160 
LDL-110 
HDL-34 
Wnl Normal 
diastolic 
function 
38. PRABHU 43M Nil Nil 97 5.9 22.7 0.8 NAD Nil TC-185 
TGL-146 
LDL-140 
HDL-39 
Wnl E/A-0.8 
IVRT-106msec 
DT-225 msec 
39. KARUPPAIH 47M Nil  Nil  94 6.0 22.6 0.7 NAD Nil  TC-150 
TGL-100 
LDL-85 
HDL-36 
Wnl Normal 
diastolic 
function 
40. PREMA 50F Nil Nil 91 5.4 21.9 0.7 NAD Nil TC-170 
TGL-140 
LDL-130 
HDL-38 
Wnl Normal 
diastolic 
function 
41. MARIAMMAL 64F Nil Nil 86 6.2 27.3 1.3 NAD Nil TC-180 
TGL-130 
LDL 
115 
HDL-35 
Wnl Normal 
diastolic 
function 
42. RAJA 57M Nil  Nil  90 5.9 21.1 0.7 NAD Nil  TC-180 
TGL-130 
LDL-110 
HDL-45 
Wnl Normal 
diastolic 
function 
43. RUKMANI 45F Nil Nil 79 6.0 22.7 0.7 NAD Nil TC-190 
TGL-130 
LDL-110 
HDL-40 
Wnl Normal 
diastolic 
function 
44. JUDITH 56F Nil Nil 88 5.4 26.3 1.2 NAD Nil TC-240 
TGL-180 
LDL-160 
HDL-34 
Wnl Normal 
diastolic 
function 
45. ESAKIAPPAN 51M Nil  Nil  94 6.1 23.1 0.8 NAD Nil  TC-175 
TGL-120 
LDL 
138 
HDL-34 
Wnl Normal 
diastolic 
function 
46. PIRAMU 60F Nil Nil 91 6.3 22 0.7 NAD Nil TC-176 
TGL-120 
LDL-130 
Wnl E/A-0.8 
IVRT-106msec 
DT-225 msec 
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HDL-35 
47. KARTHIKEYAN 45M Nil Nil 82 6.2 26.2 1.2 NAD Nil TC-196 
TGL-146 
LDL-125 
HDL-30 
Wnl Normal 
diastolic 
function 
48. PONAPPAN 48M Nil  Nil  90 5.9 23.9 1.0 NAD Nil  TC-220 
TGL-170 
LDL-140 
HDL-34 
Wnl Normal 
diastolic 
function 
49. GURUVAMMAL 63F Nil Nil 76 6.0 23 0.8 NAD Nil TC-185 
TGL-146 
LDL-140 
HDL-39 
Wnl Normal 
diastolic 
function 
50. IBRAHIM 47M Nil Nil 98 6.4 24.1 1.0 NAD Nil TC-225 
TGL-202 
LDL-175 
HDL36 
Wnl Normal 
diastolic 
function 
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ANNEXURE 3 : KEY TO MASTER CHART 
Sl 
no 
Parameter Normal values 
1. FBS- FASTING BLOOD SUGAR <100 mg/dl 
2. HBA1C- GLYCATED HEMOGLOBIN <6.5 % 
3. BODY MASS INDEX 18.5-22.5 
4. WAIST HIP RATIO Male-<0.9 
Female < 0.8  
5. TOTAL CHOLESTEROL  
<200 mg/dl  Desirable  
200–239 mg/dl  Borderline high  
240 mg/dl High  
 
6. TRIGLYCERIDE <150 mg/dl 
7. LDL- CHOLESTEROL  
<70 mg/dl  Therapeutic option for very high 
risk patients  
<100 g/dl  Optimal  
100–129  
mg/dl  
Near optimal/above optimal  
130–159 
mg/dl  
Borderline high  
160–189 
mg/dl 
High  
190  mg/dl Very high  
 
8. HDL- CHOLESTEROL  
 
<40 (<1.03)  Low  
60 (1.55)  High  
 
9. ELECTROCARDIOGRAM INTERVALS 
RATE/PR SEGMENT/AXIS/QRS SEGMENT/QT 
SEGMENT/ST-T CHANGES 
 
75-100/mt/80-120 msec/Normal axis 
80-120 msec/320-400 msec/No st-t changes 
10. E/A RATIO >/= 1.5 
11. DECELERATION TIME 160-240 msec 
12. ISO VOLUMETRIC RELAXATION TIME 60-100 msec 
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ANNEXURE 4  
ABBREVIATIONS 
1. DbCM – Diabetic Cardiomyopathy 
2. ROS – Reactive Oxygen  species 
3. PKC – Protein Kinase C 
4. NFkB – Nuclear Factor kappa B 
5. T2DM – Type 2 Diabetes Mellitus 
6. AGEs – Advanced Glycation End products 
7. RAS – Renin Angiotensin System 
8. AGT II – Angiotensin II 
9. CAN – Cardiac Autonomic Neuropathy 
10. PDR – Proliferative Diabetic Retinopathy 
11. NPDR – Non Proliferative Diabetic Retinopathy 
12. LVEF – Left Ventricular Ejection Fraction 
13. IVRT – Iso Volumetric Relaxation Time  
14. DT – Deceleration Time 
15. CAD – Coronary Artery Disease 
16. ACS – Acute Coronary Syndrome 
17. DNA – Deoxy ribo Nucleic Acid 
